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Tiivistelmä/Referat – Abstract 
Heart failure is a major public health problem and a leading cause of mortality worldwide. The most common cause of heart 
failure is myocardial infarction. Following a myocardial infarction, a large number of cardiomyocytes die and cardiac muscle is 
replaced by fibrotic scar tissue. Since the adult heart has inadequate endogenous regenerative capacity, loss of muscle tissue 
often causes a progressive decrease in cardiac function eventually leading to heart failure. At the moment heart transplantation 
is the only curative treatment for heart failure, but the low number of donor hearts is limiting the use of this treatment option. As 
current drugs only slow down the progression of the disease, there is a great need for new regenerative treatments. 
 
Direct cardiac reprogramming is a new approach for generating cardiomyocytes for cardiac regeneration. Unlike pluripotent 
stem cell-based strategies, direct reprogramming enables conversion of a terminally differentiated cell type directly into another 
cell type without first producing a pluripotent intermediate. Due to their abundancy and role in the repair of myocardial injury, 
fibroblasts represent an attractive starting cell type for direct cardiac reprogramming. Fibroblasts have been directly 
reprogrammed to induced cardiomyocytes (iCMs) by overexpression of key cardiac transcription factors, microRNAs (miRNA) 
or by modulating specific signal transduction pathways with small-molecule compounds. Despite successful reports of direct 
reprogramming both in vitro and in vivo, the efficiency of direct reprogramming remains, however, too low for potential clinical 
applications. 
 
The aim of this M.Sc. thesis work was to establish direct reprogramming of mouse embryonic fibroblasts (MEFs) to iCMs by 
viral overexpression of cardiac transcription factors Hand2 (H), Nkx2.5 (N) Gata4 (G), Mef2c (M) and Tbx5 (T) and a small-
molecule compound screening platform for identifying small-molecule compounds that could enhance the reprogramming 
efficiency and potentially replace cardiac transcription factors in direct cardiac reprogramming. In accordance with previous 
publications MEFs were successfully directly reprogrammed to iCMs using both HGMT and HNGMT cardiac transcription factor 
combinations. The screening platform was tested using the TGF-β inhibitor SB431542, which has recently been reported to 
increase the cardiac reprogramming efficiency. In line with previous publications, the reprogramming efficiency was significantly 
increased by treatment with SB431542. Initial tests with other small-molecule compounds did not have a positive effect on the 
reprogramming efficiency. 
 
The results of this M.Sc. thesis work verify previous publications and demonstrate a method for in vitro small-molecule 
compound screening, which can be used to identify compounds that increase the reprogramming efficiency in direct cardiac 
reprogramming. However, the results shown here are only preliminary and more replicates are needed in order to confirm the 
current results. Nonetheless, the results of this thesis work set a foundation for finding small-molecule compounds that in the 
future might be used to target direct cardiac reprogramming as a regenerative therapy for myocardial infarction and heart 
failure. 
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Tiivistelmä/Referat – Abstract 
Sydämen vajaatoiminta on merkittävä yhteiskuntaa kuormittava terveysongelma ja yksi yleisimpiä kuolinsyitä maailmassa. Sen 
taustalla on yleensä sydäninfarkti. Infarktin seurauksena osa sydämestä joutuu hapenpuutteen vuoksi kuolioon ja tuhoutunut 
sydänlihas korvautuu arpikudoksella. Aikuisen ihmisen sydämen uusiutumiskyky on rajallinen, minkä vuoksi sydänlihasvaurio 
yleensä johtaa etenevään sydämen pumppaustehon heikkenemiseen ja lopulta vajaatoimintaan. Sydämensiirto on toistaiseksi 
ainoa parantava hoitovaihtoehto sydämen vajaatoimintaa sairastaville, mutta elinluovuttajien vähäinen määrä rajoittaa sen 
käyttöä. Koska nykyiset käytössä olevat lääkkeet vain hidastavat taudin etenemistä, tarve uusille parantaville hoitomuodoille on 
suuri. 
 
Solujen suora uudelleenohjelmointi sydänlihassoluiksi (engl. direct cardiac reprogramming) on uusi menetelmä, jolla pystytään 
tuottamaan sydänlihassoluja muista solutyypeistä sydämen regeneraatiota varten. Toisin kuin monikykyisiin kantasoluihin 
perustuvat menetelmät, solujen suora uudelleenohjelmointi mahdollistaa jo erilaistuneen solutyypin muuntamisen suoraan 
toiseksi erilaistuneeksi solutyypiksi ilman, että se ensin muodostaa monikykyisen kantasoluvälituotteen. Fibroblastit ovat 
houkutteleva solutyyppi solujen suorassa uudelleenohjelmoinnissa sydänsoluiksi, johtuen niiden runsaasta määrästä 
sydämessä sekä niiden roolista sydänlihasvaurion korjautumisessa. Fibroblasteja on onnistuttu uudelleenohjelmoimaan 
suoraan sydänsoluiksi yli-ilmentämällä sydänsoluille tyypillisiä transkriptiotekijöitä tai mikro-RNA:ita (miRNA) tai vaikuttamalla 
tiettyihin signalointireitteihin pienmolekyyleillä. Siitä huolimatta, että solujen suora uudelleenohjelmointi sydänsoluiksi on 
onnistunut sekä in vitro että in vivo, menetelmän tehokkuus on edelleen liian heikko kliinisiä sovelluksia varten. 
 
Tämän pro gradututkimuksen ensimmäisenä tavoitteena oli onnistua hiiren alkion fibroblastien (MEF-solujen, mouse embryonic 
fibroblasts) suorassa uudelleenohjelmoinnissa indusoiduiksi sydänsoluiksi (iCMs) yli-ilmentämällä transkriptiotekijöitä (Hand2 
(H), Nkx2.5 (N) Gata4 (G), Mef2c (M) ja Tbx5 (T)) virusvektoreilla. Toisena tavoitteena oli kehittää pienmolekyylien 
seulontamenetelmä, jonka avulla voitaisiin löytää pienmolekyylejä, jotka lisäävät suoran uudelleenohjelmoinnin tehokkuutta ja 
jotka voisivat mahdollisesti korvata transkriptiotekijöiden käytön suorassa solujen uudelleenohjelmoinnissa sydänsoluiksi. MEF-
solujen uudelleenohjelmointi suoraan indusoiduksi sydänsoluiksi onnistui sekä HGMT- ja HNGMT- transkriptiotekijöiden 
yhdistelmillä. Nämä tulokset ovat linjassa aikaisempien tutkimustulosten kanssa. Pienmolekyylien seulontamenetelmää 
testattiin käyttämällä transformoivaa kasvutekijä-β (engl. tranforming growth factor beta, TGF-β)-estäjää SB431542:ta, jonka on 
hiljattain raportoitu lisäävän tehokkuutta solujen suorassa uudelleenohjelmoinnissa sydänsoluiksi. Aikaisempien 
tutkimustulosten kaltaisesti SB431542 lisäsi merkittävästi suoran uudelleenohjelmoinnin tehokkuutta. Alustavissa 
seulontakokeissa muut tutkittavat pienmolekyylit eivät lisänneet uudelleenohjelmoinnin tehokkuutta. 
 
Tämän tutkimuksen tulokset vahvistavat aikaisempia tutkimustuloksia. Työssä kehitettiin in vitro pienmolekyylien 
seulontamenetelmä, jonka avulla voidaan tunnistaa pienmolekyylejä, jotka lisäävät tehokkuutta suorassa solujen 
uudeleenohjelmoinnissa sydänsoluiksi. On kuitenkin huomioitava, että tässä työssä esitetyt tulokset ovat alustavia ja lisää 
tutkimuksia tarvitaan, jotta ne voidaan vahvistaa. Tutkimuksen tulokset luovat kuitenkin pohjaa uusien pienmolekyylien 
löytämiselle, joita tulvaisuudessa mahdollisesti voidaan käyttää solujen suorassa uudelleenohjelmoinnissa sydänsoluiksi 
sydäninfarktin tai sydämen vajaatoiminnan hoidossa. 
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1  INTRODUCTION 
 
Heart failure (HF) is a major public health problem and a leading cause of mortality 
worldwide (Bui et al. 2011). It affects over 23 million people in the world and the 
prevalence is increasing due to the aging population, causing considerable health care 
costs. At the moment heart transplantation is the only curative treatment for HF, but 
the low number of donor hearts is limiting the use of this treatment option (Doppler et 
al. 2015). As current drugs only slow down the progression of the disease, the 
mortality risk 5 years after diagnosis of HF is still 45–60%. Thus, there is a great need 
for new regenerative treatment options (Bui et al. 2011). 
 
The most common cause of HF is a myocardial infarction (MI) (Bui et al. 2011). After an 
acute myocardial infarction, a large number of cardiomyocytes die due to ischemia, 
which causes an inflammatory reaction (Travers et al. 2016). As a response, cardiac 
fibroblasts (CFs) are activated and start proliferating and transdifferentiate to 
myofibroblasts that secrete increased levels of collagen and other extracellular matrix 
proteins. This ultimately leads to the formation of fibrotic scar tissue and pathological 
remodelling of the myocardium, which includes hypertrophic thickening of the left 
ventricular wall and fibrosis. The purpose of this CF-mediated response is to maintain 
the pressure-generating capacity of the heart, but since the adult heart has inadequate 
endogenous regenerative capacity, it often causes a progressive decrease in cardiac 
function eventually leading to HF.  
 
Replacing lost cardiomyocytes with new ones is a major objective in the field of 
regenerative medicine and a potential strategy for developing new treatments for MI 
and HF (Doppler et al. 2015). Direct cardiac reprogramming is new a strategy for 
cardiac regenerative therapy that targets CFs. As CFs play a major role in the 
pathogenesis of HF, they are an attractive target for future HF therapies (Travers et al. 
2016). This M.Sc. thesis work discusses the recent progress in cardiac regeneration and 
the potential of direct reprogramming of fibroblasts to cardiomyocytes as a future 
cardiac regenerative therapy. 
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2 LITERATURE REVIEW 
 
2.1 Cardiac development as the basis for cardiac regeneration 
 
The human body has a limited capacity to repair tissue and organs following injury and 
the heart is one of the least regenerative organs in the body  (Laflamme and Murry 
2011). The field of regenerative medicine aims to restore function of damaged tissue 
by replacing lost cells. Direct cardiac reprogramming aims to generate new 
cardiomyocytes as a potential treatment of MI or HF (Sahara et al. 2015). 
Understanding the major processes driving the development of cardiomyocytes and 
formation of the heart is central in developing future cardiac regenerative therapies 
such as direct reprogramming.  
 
The mammalian heart is a complex and highly specialised organ and the formation of 
the heart, cardiogenesis, is a highly controlled process that requires generation of a 
diverse set of both muscle and non-muscle cells (Brade et al. 2013). During 
cardiogenesis embryonic stem cells commit to the cardiac cell fate and undergo 
cardiac differentiation, ultimately forming the heart. Cardiac cells are derived from a 
common mesodermal progenitor cell population that during gastrulation divides into 
two different cardiac progenitor populations called the first heart field and the second 
heart field (figure 1) (Meilhac et al. 2004, Buckingham et al. 2005). Also progenitor cells 
from the proepicardial organ and cardiac neural crest cells contribute to the formation 
of the heart. 
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Figure 1. Schematic of cardiac progenitor cells, lineage specification and the major 
signalling pathways governing cardiac development in mouse embryonic development. 
Cardiac cells are derived from a common mesodermal progenitor cell that during 
gastrulation divides into two different cardiac progenitor populations, the first and the 
second heart field. These progenitors give rise to cardiomyocyes (CM) that contribute 
to distinct parts of the heart. In addition to the two heart fields also cells derived from 
the proepicardium contribute to the formation of the heart including cardiac 
fibroblasts (CF), smooth muscle cells (SMCs) and endothelial cells (EC) (Brade et al. 
2013). 
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Much is already known about the processes governing cardiac development, but there 
are still many aspects that remain unclear. Further uncovering the basic biology 
underlying cardiac development, cell lineage commitment and cardiac differentiation 
will be crucial in developing direct reprogramming into a future cardiac regenerative 
therapy. The following chapter discusses fundamentals of cardiac development, 
focusing on aspects that are important for understanding direct cardiac 
reprogramming. Insight into the development of the heart has been gained mostly 
through animal studies of mouse and chicken embryos. 
 
2.1.1 Cell types in the heart 
 
A diverse array of cell types, both muscle and non-muscle, are needed to make up the 
functional heart (Xin et al. 2013). The muscle wall, myocardium, is formed by atrial and 
ventricular cardiomyocytes and the cardiac conduction system is formed by highly 
specialised pacemaker cardiomyocytes, including cells of the sinoatrial node, 
atrioventricular node and Purkinje fibers. However, less than a third of all the cells in 
the heart are cardiomyocytes. The inner layer of tissue that lines the chambers, the 
endocardium, and the interior of blood vessels is formed by endothelial cells, while 
vascular smooth muscle cells are found in the coronary arteries and veins. Fibroblasts, 
which are connective tissue cells, were previously thought to be the most abundant 
cell type in the heart. Recent studies however suggest that fibroblasts only account for 
about 20% of the non-myocyte cells in the heart and endothelial cells are in fact the 
most abundant cell type (Pinto et al. 2016). All cell types interact with each other 
through physical contact and paracrine and endocrine factors and contribute to the 
function and properties of the heart (Tirziu et al. 2010, Xin et al. 2013). 
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2.1.2 Essential signalling pathways during cardiac development 
 
Cardiogenesis is a precise and complex process regulated by a number of signalling 
pathways and transcriptional regulators (Brade et al. 2013). Cardiac lineage 
commitment and cardiac differentiation is induced by spatiotemporal intrinsic and 
extrinsic signals and cross talk between neighbouring tissues. Central signalling 
pathways that regulate embryonic cardiac development are shown in figure 2. These 
signals direct cardiac differentiation by inducing the expression of cardiac transcription 
factor (TF) genes. 
 
 
 
 
Figure 2. Essential signalling pathways that regulate embryonic cardiac development. 
Cardiac cell fate determination requires coordination and cooperation of multiple 
signals, both positive and negative. These signals direct cardiac differentiation by 
inducing the expression of cardiac transcription factor genes. Solid lines indicate 
inducing signals, dotted lines indicate inhibiting signals and circular arrows indicate 
self-renewal (Noseda et al. 2011). 
 
Bone morphogenetic protein (BMP) signalling is an essential driver of cardiac 
development  (van Wijk et al. 2007). BMPs are a subfamily of multifunctional proteins 
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that belong to the transforming growth factor- β (TGF- β) superfamily. BMP signalling 
is critical during gastrulation and in early mesoderm formation  (Mishina et al. 1995). 
BMP signalling has also been shown to be essential in cardiac differentiation and 
maturation of second heart field progenitors (Yang et al. 2006). The role of BMPs in 
cardiogenesis is conserved in all studied species, indicating their importance for 
cardiac development (Noseda et al. 2011). 
 
The Activin/Nodal signalling pathway is critical in early vertebrate embryonic 
development during gastrulation and in the induction of most endodermal and 
mesodermal cell types, including cardiac cells (Conlon et al. 1994, Schier 2003). Like 
BMPs, Activin and Nodal are members of the TGF-β superfamily. Activin A, together 
with BMPs, has been shown to increase the efficiency of cardiac differentiation in 
human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) 
(Laflamme et al. 2007, Kattman et al. 2011). 
 
The Wnt signalling pathway plays multiple roles in cardiac development (Gessert and 
Kuhl 2010). Wnt ligands can be divided into the so called canonical Wnts (Wnt1, -2a, -
3a, and -8) that require β-catenin for signalling and to the non-canonical Wnts (Wnt5a 
and Wnt11). The canonical Wnt/ β-catenin pathway has been suggested to have a 
biphasic role during cardiogenesis: activation of the pathway is needed for gastrulation 
and mesoderm formation, while inhibition of the pathway seems to be required for 
cardiac specification  (Ueno et al. 2007, Paige et al. 2010, Sahara et al. 2015). 
Activation of non-canonical Wnt signalling seems to be required for cardiac 
specification and differentiation (Sahara et al. 2015). 
 
The fibroblast growth factor (FGFs) pathway regulates a number of biological 
processes during embryonic development including cell proliferation, differentiation, 
and migration (Turner and Grose 2010). The mammalian FGF family consists of 
approximately 20 ligands that bind to 4 transmembrane receptor tyrosine kinases 
(Fgfr1, Fgfr2, Fgfr3 and Fgfr4). Fgf8 has been shown to be important for the 
 
 
 
7 
 
development of the second heart field in mice (Ilagan et al. 2006). Studies on cultured 
mesoderm cells also indicate that cooperative signalling of certain BMPs and FGFs are 
required to induce cardiogenesis in non-precardiac mesoderm (Barron et al. 2000). 
Furthermore, expression of Fgf9, Fgf16, and Fgf20 in the mouse epicardium and 
endocardium during embryonic development has been associated with myocardial 
proliferation and differentiation (Lavine et al. 2005).  
 
Several other signalling pathways in addition to those described above are involved in 
cardiac development, such as hedgehog signalling, Notch signalling and retinoic acid 
signalling (Noseda et al. 2011). Cardiac cell fate determination requires coordination 
and cooperation of multiple signals, both positive and negative. Unveiling signalling 
pathways that drive cardiac development has been crucial in the development of 
potential cardiac regenerative therapies (Sahara et al. 2015). Increased understanding 
of the molecular pathways that regulate cardiac differentiation has led to the 
development of several strategies to generate cardiomyocytes for cardiac replacement 
therapies, including direct cardiac reprogramming. These central signalling pathways 
are also potential drug targets when screening for small-molecule compounds that 
could increase the efficiency of direct cardiac reprogramming or even replace cardiac 
TFs altogether.  
 
2.1.3 Transcriptional regulation of cardiogenesis 
 
Transcription factors are proteins that control gene expression by binding to specific 
sequences in DNA and regulating the transcription of target genes to messenger RNA 
(mRNA) (Kohli et al. 2011). They regulate gene transcription in response to intrinsic or 
extrinsic signals. Furthermore, certain micro-RNAs (miRNAs) and epigenetic 
mechanisms, such as chromatin remodelling and histone modification participate in 
regulating gene expression. 
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Cardiac TFs are downstream targets of cardiac signalling pathways and they regulate 
cardiac development by controlling the spatiotemporal expression patterns of cardiac 
genes (Kohli et al. 2011). The evolutionarily conserved cardiac TF network is essential 
for cardiac cell fate determination, differentiation and morphogenesis. The core 
transcriptional network involved in gene regulation during cardiac development 
includes NK2 homeobox protein 5 (Nkx2.5), Myocyte-specific enhancer factor 2C 
(Mef2c), Heart- and neural crest derivatives-expressed protein 1 and 2 (Hand1 and 
Hand2), T-box transcription factor 5 (Tbx5) and GATA binding protein 4 (Gata4). These 
cardiac TFs have also proven to be essential tools in direct cardiac reprogramming. 
 
Among the earliest cardiac TFs expressed in embryonic cardiac progenitor cells are 
Nkx2.5, a member of the NK homeobox gene family and Gata4, a member of the 
double zinc-finger TF family Gata (Lints et al. 1993, Akazawa and Komuro 2005, Kohli et 
al. 2011). Despite its early expression, Nkx2.5 has been shown to be important in later 
stages of cardiac development, rather than earlier stages of cardiogenesis (Lyons et al. 
1995). The importance of Gata4 in cardiogenesis has been evidenced by loss of 
function studies: mice embryos lacking normal Gata4 had severe morphogenic defects 
and were unable to form the linear heart tube, which resulted in lethality between 
E7.0 and E9.5 (Molkentin et al. 1997). Gata4 has been shown to also physically interact 
with several other cardiac TFs, including Gata6, Nkx2.5, Hand2, Tbx5 and Mef2c, to 
cooperatively or synergistically activate cardiac genes (Charron et al. 1999, Morin et al. 
2000, Dai et al. 2002, Garg et al. 2003, Zhang et al. 2007, Kinnunen et al. 2015, Luna-
Zurita et al. 2016).  
 
Another key cardiac TF is Mef2c, which belongs to the myocyte-specific enhancer 
factor 2 (Mef2) family (Morin et al. 2000). Mef2 TFs participate in the regulation of 
skeletal and cardiac muscle cell differentiation and several important myogenic genes 
have promoters that bind Mef2 TFs (Black and Olson 1998). Loss-of-function studies 
have shown that Mef2c is essential for cardiac myogenesis and right ventricular 
development (Lin et al. 1997). Loss of Mef2c function has also been associated with 
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down-regulation of the gene encoding for the basic helix-loop-helix TF Hand2. Hand2 
has together with Hand1 been shown to be essential for the development of the 
ventricles (Srivastava et al. 1997, Firulli et al. 1998).  
 
Furthermore, the TF Tbx5 is an essential regulator of cardiac development (Plageman 
and Yutzey 2005). It belongs to the family of T-box containing TFs that are especially 
important for cardiac lineage determination and the development of the chambers 
and the conductive system. The importance of Tbx5 in heart development was first 
discovered when it was shown that a mutation in the Tbx5 gene is the cause of Holt-
Oram syndrome, a genetic disorder characterised by structural defects of the heart 
and limbs (Basson et al. 1997). In mice lacking both Tbx5 alleles the expression of 
several cardiac genes, including natriuretic peptide A (Nppa) and gap junction protein 
alpha 5 (Gja5), was decreased and severe underdevelopment and defects were 
observed in the developing heart (Bruneau et al. 2001). 
 
Several other TFs, in addition to the core cardiac TF network, are involved in the 
regulation of cardiac development. Even though many of the key regulators are well 
known, the interactions and the way these TFs work together to regulate the 
development of the heart remains poorly understood. Also, the importance of 
epigenetic regulation of gene expression is becoming more and more apparent. 
 
2.2 Strategies for generating new cardiomyocytes 
 
Replacing lost cardiomyocytes with new ones is a major goal in regenerative medicine 
and a potential strategy for developing new treatments for HF. There have already 
been some initial clinical cell transplantation trials with autologous cardiac progenitor 
cells, but the results from these studies are inconclusive (Yacoub and Terrovitis 2013). 
The growing field of stem cell research has, however, opened new potential and 
interesting strategies for cardiac regeneration. The following chapter reviews some of 
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the current promising strategies for generating new cardiomyocytes for cardiac 
regeneration (figure 3). 
 
 
Figure 3. A schematic illustration of different strategies currently being investigated for 
cardiac regeneration. Following a myocardial infarction, a large number of 
cardiomyocytes die and cardiac muscle is replaced by fibrotic scar tissue. Since the 
adult heart has inadequate endogenous regenerative capacity, loss of muscle tissue 
often causes a progressive decrease in cardiac function eventually leading to heart 
failure. Therefore, replacing lost cardiomyocytes with new ones is a major goal in 
regenerative medicine and a potential strategy for developing new treatments for 
myocardial infarction and heart failure (Addis and Epstein 2013). 
 
2.2.1 Stimulating cardiomyocyte proliferation  
 
Adult mammalian cardiomyocytes have a limited regenerative capacity and it has long 
been thought that cardiomyocytes exit the cell cycle after birth and are unable to 
proliferate (Sahara et al. 2015). Recently this paradigm has been questioned, as an 
increasing amount of evidence indicate that mammalian cardiomyocytes are actually 
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able to renew themselves, but the turnover rate is very slow and inefficient (Bergmann 
et al. 2009, Porrello et al. 2011). This has provoked great interest in finding ways to 
stimulate this innate regenerative capacity, as it is a potential strategy for replacing 
lost cardiomyocytes following cardiac injury.  
 
Regeneration of cardiac tissue and cardiomyocytes has traditionally been studied in 
lower vertebrates. In contrast to mammals, many amphibians and fish efficiently 
regenerate cardiac tissue following injury (Sahara et al. 2015). Research in zebrafish 
has shown that the adult zebrafish heart can regenerate fully after amputation of up to 
20% of the ventricle and the regenerative capacity does not decrease with age (Poss et 
al. 2002, Raya et al. 2003, Itou et al. 2012). Recent lineage-tracing studies demonstrate 
that these new cardiomyocytes are generated through proliferation of pre-existing 
mature cardiomyocytes (Jopling et al. 2010, Kikuchi et al. 2010). These studies have 
also showed that prior to re-entering the cell cycle and proliferating, zebrafish 
cardiomyocytes undergo partial dedifferentiation by disassembling their sarcomeric 
structure and start expressing cardiac TF Gata4 and cell-cycle regulators. In most 
mammals, a large percentage of adult cardiomyocytes are binucleated with very stable 
sarcomeric structures, which might prevent them from re-entering the cell cycle 
(Paradis et al. 2014). 
 
Also mammalian cardiomyocytes seem to have some regenerative capacity. Neonatal 
mouse hearts have been shown to regenerate after partial surgical resection during 
the first days following birth, but this capacity is lost by the age of 1 week (Porrello et 
al. 2011). This suggests that mammalian postnatal hearts possess a regenerative 
capacity, but it is inhibited or turned off in adult cardiomyocytes. Also adult 
mammalian cardiomyocytes have been shown to have some capacity for 
cardiomyocyte renewal, but the turnover rate is very low (Bergmann et al. 2009, 
Mollova et al. 2013, Senyo et al. 2013). Even though the regenerative capacity seems 
to be slightly increased following cardiac injury, it decreases with age and is too 
inefficient to regenerate the heart following myocardial infarction. There is also some 
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uncertainty to the source of these new cardiomyocytes. According to recent studies, 
pre-existing cardiomyocytes that undergo dedifferentiation and then proliferation are 
the main source of new cardiomyocytes, but cardiac progenitor cells have also been 
shown to contribute to cardiomyocyte renewal especially after cardiac injury (Hsieh et 
al. 2007, Malliaras et al. 2013, Senyo et al. 2013).  
 
These findings suggest that adult mammalian cardiomyocytes also have the capacity to 
proliferate, but there are some mechanisms that inhibit proliferation in adult cells. 
Ongoing research is now focusing on finding central signalling pathways that control or 
inhibit post-natal cardiomyocyte proliferation as they are potential therapeutic targets 
for cardiac regeneration. One such pathway is the p38 MAPK signalling pathway. 
Inhibition of the p38 MAP kinase has been shown to be important for cardiomyocyte 
proliferation in both zebrafish and rats (Engel et al. 2005, Jopling et al. 2012). Inhibition 
of the homeodomain TF Meis1 has also been shown to stimulate cardiomyocyte 
mitosis in adult mice (Mahmoud et al. 2013). Certain microRNAs (miRNAs) have also 
been investigated for their therapeutic potential, including miR-590 and miR-199a 
(Eulalio et al. 2012).  
 
Although knowledge about the mechanisms involved in cardiac regeneration in 
zebrafish and neonatal mice has opened new possibilities for stimulating 
cardiomyocyte proliferation in humans, much is still unknown and research is in early 
stages. A study by Andersen et al. (2014) was unable to repeat the findings about 
cardiac regeneration in neonatal mice by Porello et al. (2011), questioning the 
regenerative capacity of the neonatal mammalian heart. Even though a number of 
other investigators have been able to confirm the results by Porello et al. (2011) there 
is still some question to what extent the mammalian heart is capable of regeneration 
(Sadek et al. 2014). 
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2.2.2 Cardiac differentiation of pluripotent stem cells 
 
Cardiomyocytes can be generated from pluripotent stem cells in vitro for 
transplantation purposes by directed differentiation of embryonic stem cells (ESCs) or 
induced pluripotent stem cells (iPSCs) (Sahara et al. 2015). Embryonic stem cells are 
cells derived from the inner cell mass of a blastocyst at an early stage of 
embryogenesis (Dixit and Katare 2015). They are pluripotent, meaning that they have 
the potential to differentiate to cells of any of the three germ layers (mesoderm, 
ectoderm, and endoderm) and the capacity to proliferate indefinitely. Human 
embryonic stem cells (hESCs) were first isolated by Thomson et al. (1998) and have 
since been used as a source for in vitro cardiomyocytes. There are, however, many 
issues associated with the use of hESCs, such as teratoma formation and potential 
immune rejection of transplanted allogenic cells (Nussbaum et al. 2007). The use of 
hESCs has also raised ethical concerns as they are isolated from human embryos 
(Garbern and Lee 2013). 
 
In 2006 Takahashi and Yamanaka made the discovery that fully differentiated mouse 
fibroblasts could be reprogrammed to an embryonic pluripotent stem cell-like state by 
retroviral overexpression of the TFs Oct3/4, Sox2, c-Myc and Klf4. These cells, termed 
induced pluripotent stem cells (iPSCs), had similar characteristics as ESCs including the 
ability to differentiate to any cell of the three germ layers. The following year human 
fibroblasts were also successfully reprogrammed to iPSCs (hiPSCs), opening new 
possibilities to generate patient-specific cells for disease modelling and regenerative 
therapies and overcoming many of the issues associated with hESCs (Takahashi et al. 
2007, Yu et al. 2007). Induced pluripotent stem cell technology introduced a new way 
of generating cardiomyocytes for cardiac regeneration and in 2009 two independent 
groups were the first to differentiate iPSCs to cardiomyocytes (Zhang et al. 2009, Zwi 
et al. 2009).  
 
A number of cardiac differentiation protocols have been developed for both hESCs and 
hiPSCs over the years and the efficiency of cardiac differentiation has been improved 
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by optimisation of the differentiation protocol and the addition of different agents 
acting on specific cardiogenic signalling pathways (Sahara et al. 2015). Generally two 
different techniques have been employed: embryonic body (EB) formation, where EBs 
spontaneously differentiate to derivatives of all three primary germ layers, and 
monolayer differentiation. In one of the earliest attempts to differentiate hESCs to 
cardiomyocytes, Kehat et al. (2001) generated cardiomyocytes utilizing the EB 
formation technique, but the method was very inefficient and spontaneously 
contracting areas were seen in only 8,1% of the EBs. Also early studies with iPSCs 
utilizing the serum-dependent spontaneous EB formation technique resulted in poor 
cardiomyocyte yields (Zhang et al. 2009, Zwi et al. 2009).  
 
Laflamme et al. (2007) showed that the efficiency of cardiac hESC differentiation can 
be increased to over 30% by using a serum-free monolayer differentiation protocol 
with timed addition of activin A and BMP-4. Several protocols mimicking the signalling 
environment of embryonic cardiac development have also been developed for iPSCs 
resulting in increased cardiomyocyte yields and purity (Mummery et al. 2012). 
Recently a robust cardiac differentiation technique using small-molecule compounds 
to temporally modulate the canonical Wnt signalling pathway was shown to generate 
up to 98% cardiomyocytes (Lian et al. 2012).  
 
In vivo transplantation studies in rodents have shown that cardiomyocytes derived 
from hESCs can integrate with the host myocardium and improve cardiac function 
after injury (Caspi et al. 2007, van Laake et al. 2007, Shiba et al. 2012). Promising 
results have also been obtained in non-human primates, as a recent study showed that 
transplanted hESC-derived cardiomyocytes generated remuscularisation of the 
infarcted monkey heart (Chong et al. 2014). This study however also highlighted some 
of the risks associated with PSC derived cardiomyocyte transplantation, as most of the 
transplanted cardiomyocytes were only partially mature and diverse in phenotype, 
causing non-lethal ventricular arrhythmias in the treated monkeys. These risks and 
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others, such as potential tumour formation, need to be addressed before either hESC 
or iPSC derived cardiomyocytes can be used for clinical applications.  
 
2.2.3 Direct cardiac reprogramming of somatic cells 
 
An upcoming and alternative approach for generating cardiomyocytes is direct cardiac 
reprogramming, also known as direct lineage reprogramming or transdifferentiation 
(Addis and Epstein 2013). Unlike pluripotent reprogramming, direct reprogramming 
enables conversion of a fully differentiated somatic cell directly into another cell type 
without first producing a pluripotent intermediate. It involves a change of the gene 
expression pattern from one cell type into another, which is achieved by 
overexpression of key lineage-specific TFs, with microRNAs (miRNA) or by modulating 
specific signal transduction pathways with small-molecule compounds.  
 
Direct reprogramming is a promising new approach for cardiac regeneration as it is 
faster compared to iPSC generation and could potentially be achieved in situ without 
the need for cell transplantation (Sahara et al. 2015). The research is however in early 
stages and challenges including low efficiency and use of viral vectors need to be 
overcome before potential clinical applications. Direct reprogramming and the 
generation of cardiomyocytes using the direct reprogramming method will be 
discussed in more detail in the following chapter. 
 
2.3 Direct reprogramming of fibroblasts to cardiomyocytes 
 
Direct reprogramming is defined as the conversion of a fully differentiated cell type 
into another without going through a pluripotent intermediate. Direct reprogramming 
can be dated back to the 1980’s, when it was first discovered that ectopic expression 
of the muscle-specific master regulator TF MyoD, was sufficient to convert fibroblasts 
to cells with myogenic features (Davis et al. 1987). Following this discovery, there was 
great interest in finding other single TFs that could directly convert somatic cells into 
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other cell types. However, no similar master regulators were found for other cell 
lineages, including cardiomyocytes, and for years it seemed that direct reprogramming 
was only possible within closely related cell lineages.  
 
The research of direct reprogramming took a new direction, after the discovery that 
somatic cells could be reprogrammed to iPSCs by viral overexpression of a combination 
of TFs (Takahashi and Yamanaka 2006). This discovery inspired researchers to look for 
TF combinations that would allow for direct reprogramming to specific cell types 
across germ layers. As a result, terminally differentiated somatic cells have since been 
directly reprogrammed into a variety of cell types, including neurons, β-cells, 
hepatocytes, and cardiomyocytes, using viral overexpression of lineage specific TF 
combinations (Zhou et al. 2008, Ieda et al. 2010, Vierbuchen et al. 2010, Huang et al. 
2011). 
 
Direct reprogramming offers an alternative for generating cardiomyocytes for cardiac 
regeneration with several advantages compared to iPSC methods. By bypassing the 
pluripotent state, cardiomyocyte generation by direct reprogramming is both faster 
and easier than iPSC based cardiac reprogramming and the risk for teratoma formation 
is smaller (Addis and Epstein 2013). Direct reprogramming also offers a potential 
solution to the problems related to cell transplantation, as in vivo direct 
reprogramming would allow for conversion of endogenous fibroblasts in the heart to 
cardiomyocytes and would thus not involve cell transplantation. However, there are 
still many challenges associated with direct reprogramming, including low efficiency 
and varying results between different groups. Also the mechanisms behind direct cell 
conversion remain unclear, which might prevent the development of efficient direct 
reprogramming protocols. The progress of direct reprogramming in the field of cardiac 
regeneration will be discussed in the following. A summary of published reports of in 
vitro and in vivo direct cardiac reprogramming are presented in table 1 and table 2. 
 
 
 
 
17 
 
2.3.1 The starting cell population 
 
Functioning cardiomyocytes are vital for a healthy heart, but they only account for less 
than a third of the total number of cells in the heart (Xin et al. 2013). The adult heart is 
composed of a wide array of different cell types including vascular cells and CFs. 
Cardiac fibroblasts are connective tissue cells that support the structure of the heart 
and play a key role in the formation of scar tissue and fibrosis following cardiac injury. 
Due to their abundancy in the heart and their role in the pathogenesis of congestive 
heart disease, fibroblasts have been an attractive starting cell type for cardiac 
reprogramming. 
 
Several different types of fibroblasts have been employed for direct cardiac 
reprogramming, including CFs, mouse embryonic fibroblasts (MEFs), tail tip fibroblasts 
(TTFs), dermal fibroblasts (DFs) and human foreskin fibroblasts (FFs) (Doppler et al. 
2015). The choice of fibroblast type can however have a great effect on the 
reprogramming efficiency as the different fibroblast types have different properties 
and some fibroblast types are more amenable to reprogramming than others 
(Srivastava and Ieda 2012). Embryonic fibroblasts are generally considered easier to 
convert as they are still immature and have higher plasticity (Doppler et al. 2015). 
Cardiac fibroblasts are also considered easier to convert to cardiomyocytes, as they 
and cardiomyocytes are derived from a common progenitor cell type and therefore 
might have fewer epigenetic barriers preventing reprogramming. Cardiac fibroblasts 
have also been shown to express higher levels of a number of cardiac genes, including 
Gata4, Tbx20, Tbx5, Nkx2-5, Hand2 and Mef2c, when compared with tail fibroblasts 
and might thus be more amenable to direct cardiac reprogramming (Furtado et al. 
2014). However, with the use of CFs there is also a risk for cardiomyocyte 
contamination when isolating the fibroblasts, which might lead to false positives 
(Srivastava and Ieda 2012).  
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Table 1. Published reports of in vitro direct cardiac reprogramming. CF = cardiac 
fibroblast, TTF = tail tip fibroblast, MEF = mouse embryonic fibroblast, FF = foreskin 
fibroblast, DF = dermal fibroblast, ESC = embryonic stem cell, cTnT = cardiac troponin 
T, α-MHC = alpha myosin heavy chain, MI = myocardial infarction, iCM = induced 
cardiomyocyte. 
Reference  Species  Starting cell type Reprogramming 
factors 
Outcome measure 
Ieda et al. 
2010 
Mouse Post-natal CFs and 
TTFs 
Gata4, Mef2c, Tbx5 α-MHC reporter/cTnT 
Efe et al. 
2011 
Mouse MEFs Oct4, Sox2, Klf4, c-My 
+ JAK-inhibitor 
cTnT 
Chen et al. 
2012 
Mouse CFs and TTFs Gata4, Mef2c, Tbx5 α-MHC Nkx2.5/cTnT 
reporters 
Jayawardena 
et al. 2012 
Mouse Neonatal CF, adult 
CF and TTFs 
miR-1, -133, -208, -
499 + JAK-inhibitor 
α-MHC-CFP reporter 
Protze et al. 
2012 
Mouse MEFs and 
neonatal CFs 
Tbx5, Mef2c, Myocd α-MHC reporter/cTnT 
Song et al. 
2012 
Mouse Adult CFs and 
TTFs 
Gata4, Hand2, Mef2c, 
Tbx5 
α-MHC reporter/cTnT 
Inagawa et 
al. 2012 
Mouse Adult CFs Gata4, Mef2c, Tbx5 α-MHC reporter 
Addis et al. 
2013 
Mouse MEFs and adult 
CFs 
Hand2, Nkx2-5, 
Gata4, Mef2c, Tbx5 
functional cTnT-GCaMP 
calcium reporter 
Christoforou 
et al. 2013 
Mouse MEFs Gata4, tbx5, Mef2c, 
Srf, Myocd, Smarcd3, 
Mesp1 
MHC-GFP reporter 
Nam et al. 
2013 
Human  Neonatal FFs, 
adult CFs and 
neonatal DFs 
GATA4, HAND2, 
MYOCD, TBX5, miR-1,  
miR-133 
cTnT 
Fu et al. 2013 Human ESC-derived 
fibroblasts, fetal 
CFs and neonatal 
DFs 
GATA4, MEF2C, TBX5, 
ESRRG, MESP1, 
MYOCD, ZFPM2 
αMHC-reporter + cTnT 
Wada et al. 
2013 
Human CFs and DFs GATA4, MEF2C, TBX5, 
MESP1, MYOCD 
α-actinin and cTnT 
Ifkovits et al. 
2014 
Mouse MEFs and adult 
CFs 
Hand2, Nkx2-5, 
Gata4, Mef2c, Tbx5 + 
SB431542 
functional cTnT-GCaMP 
calcium reporter 
Wang et al. 
2014 
Mouse  MEFs and TTFs Oct4 + small molecule 
cocktail 
beating iCMs 
Wang et al. 
2015 
Mouse CFs polycistronic Mef2c-
Gata4-Tbx5 
cTnT 
Fu et al. 2015 Mouse  MEFs small molecule 
cocktail 
α-actinin 
Zhao et al. 
2015 
Mouse MEFs Gata4, Hand2, Mef2c, 
Tbx5 + TGF-β 
inhibitor A83–01 
cTnT 
Zhou et al. Mouse MEFs Gata4, Hand2, Mef2c, cTnT 
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2015 Tbx5, Akt/PKB 
Cao et al. 
2016 
Human FFs small molecule 
cocktail 
beating iCMs 
 
Table 2. Published reports of in vivo cardiac reprogramming. MI = myocardial 
infarction, cTnT = cardiac troponin T, α-MHC = alpha myosin heavy chain, CFP = 
cyanide fluorescent protein, EF = ejection fraction  
Reference  Specie
s  
in vivo model Reprogramming 
factors 
Outcome measure 
Jayawardena 
et al. 2012 
Mouse MI-model miR-1, -133, -208, -
499  
lineage tracing and α-
MHC-CFP reporter 
Qian et al. 
2012 
Mouse MI-model Gata4, Mef2c, Tbx5 lineage tracing, α-
actinin 
Song et al. 
2012 
Mouse MI-model Gata4, Hand2, 
Mef2c, Tbx5 
lineage tracing, cTnT 
Inagawa et 
al. 2012 
Mouse MI-model Gata4, Mef2c, Tbx5 α-MHC reporter, α-
actinin 
Mathison et 
al. 2012 
Mouse MI-model polycistronic Gata4-
Mef2c-Tbx5 
Fibrosis ↓, EF ↑ 
Jayawardena 
et al. 2015 
Mouse MI-model miR-1, -133, -208, -
499 
Lineage-tracing, cTnT 
Ma et al. 
2015 
Mouse MI-model polycistronic Mef2c-
Gata4-Tbx5 
Lineage-tracing, 
α-actinin 
 
2.3.2 Transcription factor-mediated direct cardiac reprogramming of murine 
fibroblasts to induced cardiomyocytes 
 
Successful direct reprogramming of terminally differentiated somatic cells to 
cardiomyocytes was first reported by Ieda et al. (2010). They identified a combination 
of three cardiac TFs, Gata4, Mef2c, and Tbx5 (GMT), which were sufficient for 
converting mouse cardiac and DFs into cardiomyocyte-like cells in vitro. Using a 
transgenic reporter system where green fluorescent protein (GFP) was driven by an α-
myosin heavy chain (α-MHC) promoter, which is activated in mature cardiomyocytes, 
and flow cytometry for quantification, they showed that lentiviral expression of GMT 
resulted in 20% α-MHC–GFP+ cells. These cells were termed induced cardiomyocytes 
(iCMs). The reprogramming was demonstrated to be direct using genetic lineage 
tracing, which showed that iCMs did not express cardiac progenitor markers (Mesp1 
and Isl1) during the reprogramming process.  
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These results were the first to confirm that direct reprogramming to cardiomyocytes 
was possible. However, when examining these results, it is important to keep in mind 
that only a third of these cells expressed sarcomere marker cardiac troponin T (cTnT) 
and only few cells started beating spontaneously after 4–5 weeks in culture (Ieda et al. 
2010). It is therefore likely that the majority of iCMs were only partially reprogrammed 
and the actual reprogramming efficiency was much lower than reported. 
 
The effectiveness of the GMT TF combination was later questioned by Chen et al. 
(2012), who reported that lentiviral expression of GMT factors in mouse TTFs and CFs 
only resulted in partial and insufficient cardiac reprogramming. They reported that 
despite significant overexpression of GMT, no α-MHC or Nkx2.5 expression was 
detected. Expression of cTnT was however detected in 35% of the cells, but no 
spontaneously beating cells were seen.  
 
The reason why Chen et al. (2012) were unable to reproduce the results by Ieda et al. 
(2010) is unclear, but might be explained with differences in the reprogramming 
protocols. Recently Wang et al. (2015) demonstrated that the optimal stoichiometry of 
G, M, T TF expression greatly influences the reprogramming efficiency in vitro. Using a 
polycistronic vector that expressed different levels of TFs depending on the splicing 
order, they found that the vector expressing a higher level of Mef2c and lower levels of 
Gata4 and Tbx5 resulted in a significantly higher reprogramming efficiency than 
separate transduction of GMT. These results suggest that also non-optimal expression 
levels of GMT might be the reason for unsuccessful reprogramming experiments.  
 
Since the initial report by Ieda et al. (2010), several other TF combinations have been 
examined and additional TFs have been reported to improve direct reprogramming of 
fibroblasts to iCMs. Song et al. (2012) showed that the addition of Hand2 to the GMT 
combination resulted in a higher reprogramming efficiency compared with just GMT. 
Like Ieda et al. (2010), they used an α-MHC-GFP reporter to screen for the optimal TF 
combination in adult mouse TTFs. The combination of GMT + Hand2 (GHMT) 
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generated iCMs with an average efficiency of 9.2%, while GMT only converted an 
average of 2.9% of the transduced cells.  
 
Addis et al. (2013) used a functional reporter system, in which a GCaMP calcium 
indicator is driven by a cTnT promoter, to evaluate the optimal TF combination for 
direct cardiac reprogramming in MEFs. They identified the combination of Hand2, 
Nkx2.5, Gata4, Mef2c, and Tbx5 (HNGMT) as the most effective TF combination. 
Lentiviral transduction of the HNGMT combination was reported to be 52-fold more 
efficient compared with GMT.  
 
In addition to the above described TF combinations several other TFs, including 
myocardin (Myocd), Mesp1, Smarcd3 and SRF have been reported to enhance the 
reprogramming efficiency in addition to GMT (Sahara et al. 2015). Also different 
screening methods have been employed to identify the most optimal factor 
combination. Protze et al. (2012) used an alternative method for identifying 
reprogramming factors. Instead of using a screening system relying on only one 
reporter gene, they used a system that assessed the ability of different TF 
combinations to activate the expression of five cardiac genes (Myh5, Myl2, Actc1, 
Nkx2.5 and Scn5a) in mouse fibroblasts. As a result, they found that the combination 
of Tbx5, Mef2c and Myocd upregulated a broader spectrum of cardiac genes than the 
GMT combination. 
 
2.3.3 MicroRNA-mediated direct reprogramming 
 
Micro-RNAs (miRNAs) are a class of small, single-stranded, non-coding RNA that act as 
negative regulators of gene expression (Katz et al. 2016). miRNAs have been shown to 
play an important role in cardiac development and are important regulators of cell fate 
determination and differentiation. They have also been recognised as potential 
mediators of direct cardiac reprogramming.  
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Jayawardena et al. (2012) identified a combination of miRNAs (miR-1, -133, -208, -499) 
that were able to directly convert neonatal mouse fibroblasts into iCMs both in vitro 
and in vivo. Using a transgenic αMHC-CFP (cyan fluorescent protein) reporter cell line 
to assess reprogramming efficiency, they found that transfection with the miRNA 
combination resulted in αMHC activation in approximately 1.5–7.7% of transfected 
fibroblasts. Direct cardiac reprogramming with miRNAs has also been examined by 
Muraoka et al. (2014), who found the addition of miR-133 to the GMT TF combination 
to result in up to 7-fold more beating cells compared with GMT alone in MEFs. They 
were however unable to convert MEFs into iCMs using the same miRNA combination 
as previous reported by Jayawardena et al. (2012). Overall, these studies suggest that 
miRNAs could potentially be used for cardiac regenerative medicine to replace lost 
cardiomyocytes. In contrast to viral delivery of cardiac TFs, miRNAs do not have a risk 
of genomic integration, making them more feasible for clinical use.  
 
2.3.4 Direct reprogramming of human fibroblasts to induced cardiomyocytes 
 
One of the ultimate goals for direct cardiac reprogramming is to be able to utilise the 
technique for cardiac regenerative medicine (Addis and Epstein 2013). A necessary 
step toward potential clinical applications is to transfer the direct reprogramming 
technique from murine fibroblasts to human fibroblasts. This has however proven to 
be challenging, as the gene regulatory networks in human cells are different and more 
complex than those in mouse cells (Sahara et al. 2015). The same reprogramming 
factor combinations that have converted mouse fibroblasts to iCMs seem to be 
insufficient for reprogramming human fibroblasts to iCMs and additional TFs are 
necessary (Fu et al. 2013, Nam et al. 2013).  
 
Nam et al. (2013) were the first to achieve successful direct reprogramming of human 
fibroblasts to iCMs. They found that a combination of GATA4, TBX5, HAND2, MYOCD, 
miR-1 and miR-133 converted neonatal and adult human FFs to iCMs that expressed 
cardiac markers and had sarcomere-like structures. The reprogrammed cells also 
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displayed calcium oscillations and rare cells started beating spontaneously. Direct 
reprogramming of human fibroblasts into iCMs has also been reported by Wada et al. 
(2013), who found the combination of GMT together with MESP1 and MYOCD to 
convert human cardiac and DFs to immature iCMs, and Fu et al. (2013), who achieved 
direct cardiac reprogramming using a combination of GMT together with ESRRG 
(estrogen-related receptor gamma), MESP1, MYOCD and ZFPM2 (zinc finger protein, 
FOG family member 2). 
 
Despite successful reprogramming of human fibroblasts to iCMs, all studies resulted in 
relatively immature iCMs and only rare spontaneously contracting cells were observed 
(Fu et al. 2013, Nam et al. 2013, Wada et al. 2013). Both Nam et al. (2013) and Wada et 
al. (2013) reported that the generated iCMs were morphologically immature and the 
cells only displayed slow calcium oscillations. Reprogramming of human fibroblasts 
into iCMs also seems to result in heterogeneous populations of iCMs and varying 
reprogramming efficiencies (Nam et al. 2013). However, these studies show that 
human fibroblast can also be directly reprogrammed to cardiomyocyte-like cells. 
Despite the initial success, the research is still in early stages and further research is 
needed in order to improve the efficiency and to generate mature and functional 
cardiomyocytes for clinical use. 
 
2.3.5 Direct cardiac reprogramming in vivo 
 
One of the advantages of direct cardiac reprogramming compared to iPSC-based 
methods is the possibility of converting endogenous CFs to iCMs in vivo by delivering 
reprogramming factors directly to the heart and thus avoiding cell transplantation. 
Following the first successful conversions of fibroblasts to iCMs in vitro, several groups 
began to investigate whether the same results could be achieved in vivo. 
 
Qian et al. (2012) and Song et al. (2012) were the first groups to report in vivo cardiac 
reprogramming. Qian and colleagues used genetic fate mapping to demonstrate that 
non-myocytes in the infarcted mouse heart could be reprogrammed into iCMs by 
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directly injecting retroviruses expressing GMT TFs into the mouse heart (Qian et al. 
2012). Using a Cre recombinase driven by a fibroblast marker promoter (periostin or 
Fsp1) together with an R26RlacZ reporter line, in which β-galactosidase is activated 
only in periostin-Cre-expressing cells, to label endogenous CFs and immunofluorescent 
staining with β-galactosidase and α-actinin to determine reprogramming efficiency, 
they showed that new iCMs derived from non-myocytes were generated with a 
reprogramming efficiency of 10–15%. Functional studies performed three months after 
the coronary ligation also showed a decreased degree of fibrosis and modest but 
statistically significant improvement in cardiac function.  
 
Song and colleagues used a similar lineage tracing approach (Fsp1-Cre and inducible 
Tcf21-iCre) (Song et al. 2012). They reported a reprogramming efficiency of 1–8% after 
injecting retroviral vectors expressing GHMT factors into infarcted mouse hearts in 
vivo. Even though they reported a lower reprogramming efficiency than Qian and 
colleagues, Song et al. demonstrated a greater improvement in cardiac function. In 
functional studies three months after the left coronary artery ligation, the scar size was 
reduced by 50% and the ejection fraction (EF) was increased by 2-fold compared with 
controls.  
 
Both groups reported a statistically significant improvement in cardiac function, even 
though the reprogramming efficiency remained relatively low. This suggests that there 
are other factors besides generation of iCMs contributing to the improved cardiac 
function. Song et al. (2012) speculated that mechanisms, such as decreased activation 
of CFs, enhanced survival of endogenous cardiomyocytes, enhanced differentiation of 
cardiac progenitors into cardiomyocytes or increased angiogenesis could contribute to 
the improved cardiac function. Gata4 has previously been shown to act as survival 
factor for cardiomyocytes by enhancing myocardial angiogenesis, decreasing apoptosis 
and increasing generation of cardiac stem like cells (Rysä et al. 2010). The reported 
improvement in cardiac function might therefore be partially due to overexpression of 
Gata4. 
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Inagawa and colleagues used an alternative approach to determine in vivo direct 
reprogramming by co-transducing retroviral GMT factors and a reporter gene into the 
infarcted hearts of immunosuppressed mice (Inagawa et al. 2012). Even though only 
1% of the transduced fibroblasts in the infarcted mice hearts were reprogrammed to 
iCMs, Inagawa and colleagues showed that using a polycistronic viral delivery system 
resulted in morphologically more mature iCMs compared to iCMs generated by 
separately delivered GMT factors. As a conclusion they proposed that delivery of 
reprogramming factors via a polycistronic vector might be beneficial for in vivo cardiac 
reprogramming.  
 
In a more recent study Ma et al. (2015) used a polycistronic MGT vector that expresses 
a higher level of M and lower levels of G and T for in vivo direct reprogramming in 
mice. In contrast to the results by Inagawa et al. (2012), Ma et al. (2015) showed that 
injecting mice with the MGT polycistronic vector resulted in a higher reprogramming 
efficiency compared to using separate TF vectors. These results are in line with 
previous results by the same group of the effect of TF stoichiometry on direct 
reprogramming in vitro (Wang et al. 2015). However, Ma and colleagues did not find a 
significant difference in level of iCM maturity when comparing reprogramming with 
the polycistronic MGT and traditional GMT TF delivery with separate vectors. 
 
In addition to traditional TF-mediated direct reprogramming, several groups have 
attempted alternative methods also for in vivo cardiac reprogramming. Mathison et al. 
(2012) were able to improve cardiac function by injecting vascular endothelial growth 
factor (VEGF) to infarcted rat harts 3 weeks prior to GMT TF gene delivery. They 
reported that treatment with GMT and VEGF increased the ejection fraction by 4-fold 
compared to treatment with GMT alone. In vivo cardiac reprogramming has also been 
achieved using miRNAs. Jayawardena et al. (2012) demonstrated in vivo 
reprogramming using lentiviral vectors to deliver a combination of miR-1, -133, -208, 
and -499 into infarcted Fsp1-Cre mice hearts. However cardiac function was not 
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assessed and the study did not take into consideration that some of the generated 
iCMs could be the result of cell fusion of fibroblasts with endogenous cardiomyocytes. 
Recently, also significant improvement of cardiac function, as measured by serial 
echocardiography, was demonstrated by the same group using the same miRNA 
combination (Jayawardena et al. 2015).  
 
Overall in vivo direct cardiac reprogramming seems to result in more mature iCMs and 
higher reprogramming efficiencies compared with in vitro direct reprogramming. It has 
been suggested that factors in the cardiac microenvironment such as the extracellular 
matrix and paracrine factors might be beneficial for the reprogramming process 
(Doppler et al. 2015). The higher reprogramming efficiencies achieved in vivo might 
also at least partially be explained with CFs in the heart being easier to convert to iCMs 
as they and cardiomyocytes are derived from a common progenitor cell. However, 
there have been great variations in the results reported by different groups. Like with 
in vitro reprogramming studies, some of these variations might be due to variations in 
the experimental procedures. It is none the less clear that both in vitro and in vivo 
cardiac reprogramming is still in its infancy and more comparable studies are needed. 
 
2.3.6 Underlying mechanisms of direct cardiac reprogramming 
 
Understanding the mechanism of action for direct reprogramming is of great 
importance in overcoming barriers that limit the reprogramming efficiency and 
potential clinical use. Fundamentally, converting one cell type into another involves 
epigenetic silencing of the starting cell type’s master genes and activation of the target 
cell specific gene expression (Xu et al. 2015). In direct cardiac reprogramming this 
means shifting from expression of fibroblast genes to expression of cardiomyocyte 
specific genes. Even though direct reprogramming has been applied for several 
different cell types, the mechanisms underlying these changes remain poorly 
understood. Some studies suggest that inhibition of TGF-β might be critical for direct 
reprogramming. Ifkovits et al. (2014) showed that the TGF-β inhibitor SB431542 
increased the reprogramming efficiency five-fold when used together with the NHGMT 
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TF combination. Muraoka et al. (2014) showed that direct reprogramming with GMT + 
miR-133 was mediated through suppression of TF gene Snail1, which is a downstream 
target of TGF-β. However, there are also some results contradicting this, as Fu et al. 
(2013) reported that activation of TGF-β promoted direct cardiac reprogramming of 
human fibroblasts. None the less TGF-β signalling seems to play a role in direct cardiac 
reprogramming. 
 
2.3.7 Evaluation of direct cardiac reprogramming and characterisation of induced 
cardiomyocytes 
 
To date, multiple outcome measures have been employed by different groups to 
evaluate the efficiency of direct cardiac reprogramming, causing great variations in 
reported reprogramming efficiencies and making the results of different groups 
difficult to compare with each other (Doppler et al. 2015). In order to get reliable and 
comparable results, it is important to first clearly define what features are 
characteristic for cardiomyocytes and to use unambiguous and relevant outcome 
measures (Addis and Epstein 2013). Not all reported outcome measures are equally 
reliable and less stringent outcome measures, such as the expression of single genes, 
often result in higher reprogramming efficiencies compared to more stringent 
outcome measures (Figure 4). 
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Figure 4. Reliability and stringency of different outcome measures used in direct 
cardiac reprogramming. Non-functional outcome measures, such as immunostaining of 
cardiac proteins, are easy to quantify, but usually have lower stringency compared to 
functional measurements. Functional outcome measures, such as detection of calcium 
oscillation, action potentials and spontaneous contraction, require the activation and 
coordination of several cardiac genes, making them more stringent and reliable. A 
combination of several outcome measures is generally required in order to get a 
reliable result (Doppler et al. 2015).  
 
Both non-functional- and functional outcome measures have been used to evaluate 
direct cardiac reprogramming. Non-functional outcome measures include detection of 
cardiomyocyte-specific gene activation, immunostaining of cardiac proteins and 
activation of reporter transgenes driven by cardiomyocyte-specific gene promoters 
(Doppler et al. 2015). These readouts are easy to quantify and can be detected at an 
early stage post-induction, making them feasible for large scale screening. However, 
they usually also have lower stringency compared to functional measurements and can 
result in false positives that can be hard to rule out (Addis and Epstein 2013). 
Functional outcome measures, such as detection of calcium oscillation, action 
potentials and spontaneous contraction, require the activation and coordination of 
several cardiac genes, making these outcome measures more stringent and reliable.  
 
There are no universal standards for defining an iCM (Addis and Epstein 2013). 
However, a wide variety of attributes can be assessed in order to determine if a cell is 
a cardiomyocyte, including gene expression patterns, epigenetic marks and cell 
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morphology. One key feature of mature functioning cardiomyocytes is a well-
organised sarcomere structure, which can be visualised with immunostaining for 
cardiac sarcomere proteins, such as α-actinin and cTnT (Nam et al. 2014). Sarcomere 
protein expression and well-organised sarcomere structure do, however, not always 
correlate and thus evaluating reprogramming efficiency only based on sarcomere 
protein expression might lead to overestimation of the reprogramming efficiency 
(Doppler et al. 2015). 
 
The ability to generate action potentials and to contract is generally considered the 
most characteristic feature of a cardiomyocyte (Addis and Epstein 2013, Doppler et al. 
2015). Identification of spontaneously contracting cells has therefore been considered 
the most stringent outcome measure and the standard measure of success in direct 
cardiac reprogramming (Addis and Epstein 2013). The prevalence of spontaneously 
beating cells can, however, be difficult to quantify. Addis et al. (2013) described a 
method to visualise calcium oscillations and contracting cells by using a transgenic 
calcium reporter driven by the cardiac troponin T promoter, making it easier to identify 
and quantify beating cells. It should be noted, that spontaneous contraction is not a 
typical property of all mature cardiomyocytes and spontaneously beating iCMs 
identified in direct reprogramming experiments might in fact be immature 
cardiomyocytes (Addis and Epstein 2013) .  
 
A combination of several outcome measures is generally required in order to get a 
reliable result and assessing just a single feature can lead to overestimation of the 
reprogramming efficiency (Addis and Epstein 2013). In addition to choosing valid 
outcome measures, it is important to pay attention to how the reprogramming 
efficiency is reported. In contrast to the non-reprogrammed cells, iCMs usually stop 
proliferating  (Ieda et al. 2010). This can cause underestimation of the real 
reprogramming efficiency, if the efficiency is reported as the percentage of iCMs per 
total number of cells at the time of quantification (Addis and Epstein 2013). Another 
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possible way to present the reprogramming efficiency is by dividing the number of 
iCMs with the number of initially transduced cells. 
 
2.4 Direct cardiac reprogramming with small-molecule compounds 
 
2.4.1 Small-molecule compounds as regulators of gene expression 
 
Direct reprogramming is emerging as a promising alternative for generating 
cardiomyocytes for cardiac regenerative medicine, disease modelling and drug 
discovery. The use of viral vectors for delivery of TFs might however limit the clinical 
applications, as it involves a risk for genomic integration of exogenous genes into the 
host genome (Li et al. 2013). Developing methods that would avoid genetic 
manipulation is one of the major challenges facing regenerative medicine. A potential 
solution would be to use small-molecule compounds to replace viral-mediated TF gene 
transfer. Small molecules are chemical compounds with low molecular weight that 
have the ability to modulate specific protein targets rapidly and often reversibly (Yu et 
al. 2014). They are an attractive alternative to the conventional use of viral vectors, as 
they are cost-effective, easy to manipulate and standardise and concentrations can 
easily be controlled, improving both efficacy and safety, and making the approach 
more feasible for clinical applications. 
 
Small-molecule compounds have been studied extensively in iPSC reprogramming to 
reduce the number of viral vectors and to improve efficiency. In 2013 Hou et al. were 
the first to report iPSC generation using only small-molecule compounds. The use of 
small-molecule compounds in direct reprogramming is a relatively new topic and the 
published reports of the use of small-molecule compounds in direct reprogramming 
are limited. Chemically-mediated direct reprogramming is however an emerging trend 
and more and more research is focusing on finding small-molecule compounds that 
could either enhance reprogramming efficiency in combination with TFs or completely 
replace viral delivery of TFs.  
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Small-molecule compounds can work as regulators of gene expression and thus have 
an impact on cell fate (Yu et al. 2014). Generally small-molecule compounds that 
regulate gene expression can be divided into four classes based on their mechanism of 
action: signalling pathway modulators, modulators of epigenetic proteins, metabolic 
regulators and nuclear receptor agonists and antagonists (Figure 5). Signalling pathway 
modulators either activate or inhibit a component of a signalling cascade to indirectly 
regulate the expression of downstream genes. Modulators of epigenetic proteins can 
reactivate or silence genes by acting on enzymes that are involved in epigenetic gene 
regulation such as histone-modifying enzymes or enzymes that regulate DNA 
methylation. Metabolic regulators modulate metabolic pathways and nuclear receptor 
agonists or antagonists regulate gene expression directly by binding to nuclear 
receptors. 
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Figure 5. Small-molecule compounds can regulate gene expression through four 
different mechanisms: a) by activating or inhibiting signalling pathways that regulate 
transcriptional activity, b) by modulating epigenetic proteins, c) by acting as metabolic 
regulators and d) by directly activating or inhibiting nuclear receptors (Yu et al. 2014).  
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2.4.2 Advances in small-molecule compound-mediated direct reprogramming 
 
Small-molecule compounds might prove to be important tools in overcoming some of 
the major challenges involved in direct reprogramming, including low reprogramming 
efficiency, slow reprogramming process and safety issues related to the use of viral 
vectors (Li et al. 2013). Small-molecule compounds have been identified to enhance 
direct reprogramming in addition to lineage specific TFs for a number of cell types. The 
ultimate goal is to identify small-molecule compounds that could replace the use of 
TFs completely, but this has proven to be challenging. 
 
The use of small-molecule compounds in direct reprogramming has been most 
extensively investigated in the generation of neurons. There are several reports where 
small-molecule compounds have been used in direct neural reprogramming to either 
enhance the reprogramming efficiency in addition to reprogramming factors or to 
reduce the number of reprogramming factors (Ladewig et al. 2012, Liu et al. 2013 Kim 
et al. 2014). The first reports of chemical-only direct reprogramming of fibroblasts to 
neural cells without passing through a progenitor stage were published by Hu et al. 
(2015) and Li et al. (2015). These studies showed that small-molecule compounds are 
able to convert cell fate, taking direct reprogramming a huge step toward future 
clinical applications. Since these initial studies a number of additional reports of small-
molecule compound-mediated direct reprogramming to neurons have been published 
(Cheng et al. 2015, Zhang et al. 2015, Zhang et al. 2016). Additionally there have also 
been single reports of chemical-only direct reprogramming toward pancreatic cells, 
endothelial cells and cardiomyocytes (Pennarossa et al. 2013, Sayed et al. 2015, Cao et 
al. 2016). The use of small-molecule compounds in direct cardiac reprogramming will 
be reviewed in the following section. 
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2.4.3 Potential pharmacological targets in direct cardiac reprogramming 
 
Targeting direct reprogramming by pharmacological intervention is an intriguing 
strategy for cardiac regeneration. However, the underlying mechanisms of direct 
cardiac reprogramming remain mostly unknown, which has hindered specific targeting 
of direct reprogramming with small-molecule compounds. Still, understanding of the 
major signalling pathways and transcriptional regulation controlling cardiac 
differentiation during embryonic development offers potential drug targets for cardiac 
regeneration. Also recent studies have revealed a number of potential targets that 
might be pharmacologically modulated to facilitate direct reprogramming. 
 
One such potential target is the pro-fibrotic TGF- β signalling pathway. Members of the 
TGF- β superfamily bind to the type I and type II TGF- β serine-threonine kinase 
receptors that activate target gene expression by phosphorylating TFs Smad2 and 
Smad3 (Inman et al. 2002). Zhao et al. (2015) recently demonstrated that activation of 
TGF- β signalling works as a barrier to direct cardiac reprogramming by activating pro-
fibrotic signalling. They showed that treatment with the TGF- β ligand TGF- β1 
significantly reduced the reprogramming efficiency in HGMT-transduced fibroblasts. 
Further, inhibition of the pathway with a small-molecule compound TGF-β-inhibitor 
significantly increased the reprogramming efficiency and generated iCMs with a 
remarkable reprogramming efficiency of up to 67%. Inhibition of TGF- β signalling has 
also previously been reported to increase the reprogramming efficiency (Ifkovits et al. 
2014). Furthermore, TGF- β signalling is also considered as a potential drug target for 
inhibiting fibrotic remodelling of the heart (Talman and Ruskoaho 2016). TGF-β 
therefore serves as a promising potential drug target for cardiac regeneration. 
 
In addition to inhibition of TGF-β, Zhao and colleagues also showed that inhibition of 
Rho-associated kinase signalling, which is another pro-fibrotic signalling pathway, 
resulted in an increased reprogramming efficiency (Zhao et al. 2015). The fundamental 
mechanism behind direct cardiac reprogramming involves a change in cell fate by 
switching from expression of fibroblast genes to expression of cardiomyocyte specific 
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genes (Xu et al. 2015). Therefore, activating signalling pathways that inhibit the 
expression of fibroblast genes or inhibiting pro-fibrotic signalling with small-molecule 
compounds is a potential strategy for pharmacological intervention in direct cardiac 
reprogramming. Further characterisation and a more detailed understanding of the 
signalling pathways that are involved in regulating the expression of fibroblast or 
cardiac genes might lead to the discovery of new potential drug targets.  
 
Another signalling pathway that has been identified as a potential pharmacological 
target in direct cardiac reprogramming is the Akt1/Protein kinase B signalling pathway 
(Zhou et al. 2015). Zhou et al. (2015) showed that GHMT-treatment combined with 
overexpression of Akt1 significantly increased the generation of iCMs in vitro 
compared with GHMT treatment alone. They hypothesized that Akt1 likely increases 
reprogramming via a pathway activated by insulin-like growth factor 1 (IGF1) that goes 
via phosphoinositol 3-kinase (PI3K) to Akt1 and then activates downstream signals 
including the mitochondrial target of rapamycin complex 1 (mTORC1) and forkhead 
box o3 (Foxo3a). Interestingly this same pathway has previously been identified as a 
mediator of cardiac hypertrophy (Aoyagi and Matsui 2011). Zhou et al. (2015) reported 
that the reprogramming efficiency was enhanced by the addition of IGF1 to GHMT TFs, 
indicating that the increase in direct reprogramming efficiency is caused by activation 
of the IGF1 receptor. However, the reprogramming efficiency achieved with this 
combination was lower than the combination of Akt1 plus HGMT. Thus, there might be 
other mediators of Akt1 signalling that might serve as more efficient drug targets.  
 
Recent direct cardiac reprogramming research has focused on identifying epigenetic 
barriers that hinder direct cardiac reprogramming. Epigenetic gene regulation plays a 
critical role in cardiac lineage differentiation and specification by regulating the 
expression of cardiac genes (Oyama et al. 2014). Epigenetic proteins, including histone-
modifying enzymes such as histone deacetylase, histone methyltransferase and 
histone demethylase or enzymes that regulate DNA methylation, such as DNA 
methyltransferase can be modulated by small-molecule compounds (Christ et al. 
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2013). As efficient direct reprogramming requires a remodelling of the epigenetic 
landscape of the reprogrammed cell, epigenetic proteins represent attractive drug 
targets in direct cardiac reprogramming. 
 
As an example of a potential epigenetic drug target, Zhou et al. (2016) recently 
identified the polycomb complex protein Bmi1 to be a major epigenetic barrier for 
direct cardiac reprogramming. The inhibitory effect of Bmi1 on direct cardiac 
reprogramming was revealed to be partially caused by Bmi1 directly binding to the 
regulatory regions of a number of cardiogenic genes and suppressing them. Identifying 
other epigenetic barriers of direct cardiac reprogramming is an important strategy for 
increasing the reprogramming efficiency and will most likely lead to the identification 
on novel drug targets in direct cardiac reprogramming. 
 
2.4.4 Small-molecule compounds in direct cardiac reprogramming 
 
Small-molecule compounds have initially been used in direct cardiac reprogramming to 
increase reprogramming efficiency. Among the first to report the use of a small-
molecule compound to facilitate cardiac reprogramming were Efe et al. (2011), who 
showed that a small molecule Janus kinase (JAK) inhibitor in addition to overexpression 
of Oct4, Sox2, Klf4 and c-Myc in cardiomyocyte-favourable culture conditions directed 
reprogramming of MEFs directly to cardiomyocytes instead of iPSCs (Efe et al. 2011). 
Even though these results were an encouraging first step toward small-molecule 
compound-mediated direct cardiac reprogramming, Efe and colleagues could not 
altogether rule out the possibility that the cardiomyocytes were in fact derived from 
contaminating cardiac precursors or iPSC intermediates and not directly 
reprogrammed.  
 
The same group later identified a small-molecule compound cocktail consisting of TGF-
β inhibitor SB431542, glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021, lysine 
specific histone demethylase 1 (LSD1) inhibitor parnate and adenylyl cyclase (AC) 
activator forskolin that enabled direct cardiac reprogramming with only the TF Oct4 
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(Wang et al. 2014). They reported that during the reprogramming process the cells did 
pass through a cardiac precursor stage, but not through a pluripotent state. However, 
lineage tracing was not used confirm this. 
 
Ifkovits et al. (2014) set out to find small-molecule compounds that could increase 
reprogramming efficiency in addition to the HNGMT TF combination in MEFs. They 
selected small-molecule compounds that have previously been used to facilitate iPSC 
generation and cardiac differentiation and found that the TGF-β inhibitor SB431542 
increased the reprogramming efficiency up to 5 fold compared to only HNGMT. They 
further showed that inhibition of TGF-β by SB431542 increased the reprogramming 
efficiency in a dose-dependent matter. 
 
Recently there have been two different reports of small-molecule compound only-
mediated direct cardiac reprogramming. The first group to report direct cardiac 
reprogramming using only small-molecule compounds were Fu et al. (2015). They set 
out to repeat the generation of chemically induced iPSC from MEFs reported 
previously by Hou et al. (2013) but found instead that treatment with the combination 
of 6 small molecules resulted in beating clusters of cardiomyocytes (table 3) (Fu et al. 
2015). After optimisation of their protocol they reported that the generated iCMs 
expressed cardiomyocyte markers, had sarcomere structures and showed calcium 
oscillation. The cells were shown to originate from fibroblasts by lineage tracing and 
were determined to pass through a cardiac progenitor stage rather than a pluripotent 
intermediate by quantitative RT-PCR and time-lapse imaging. Even though these 
results seem promising and the implications of these results can be great, no lineage 
tracing with pluripotency factors was done to rule out the possibility that the cells 
passed through a pluripotent intermediate. 
 
Recently Cao et al. (2016) also demonstrated small-molecule compound direct cardiac 
reprogramming of human fibroblasts. They screened for small-molecule compounds 
using an α-MHC-GFP reporter to identify iCMs and found that a combination 9 
 
 
 
38 
 
different small-molecule compounds resulted in the highest reprogramming (table 3). 
After 30 days 6.6 ± 0.4% of the treated cells expressed cardiac marker cTnT and of 
these over 97% were reported to beat spontaneously. Similarly to the results by Fu et 
al. (2015) also Cao et al. (2016) reported that the cells went through a cardiac 
precursor stage before becoming iCMs. However, they did not either direct lineage 
tracing to rule out the possibility of the cells going through a pluripotent stage. 
 
Table 3. Small-molecule compounds used by Fu et al. (2015) and Cao et al. (2016) to 
achieve chemically induced direct cardiac reprogramming.  
Small-molecule compound Mechanism of action Study 
RepSox 
Transforming growthfactor (TGF)-β 
kinase/activin receptor-like kinase 
(ALK 5) inhibitor 
Fu et al. 2015 
Forskolin adenylyl cyclase (AC) activator Fu et al. 2015 
Valporic acid (VPA) 
histone deacetylase (HDAC) 
inhibitorF 
Fu et al. 2015 
Parnate 
lysine specific histone demethylase 
1 (LSD1) inhibitor 
Fu et al. 2015 
TTNPB retinoic acid analog Fu et al. 2015 
CHIR99021 
glycogen synthase kinase 3 (GSK3) 
inhibitor 
 Fu et al. 2015, 
Cao et al. 2016 
A83-01 TGF-β kinase/ ALK 5 inhibitor Cao et al. 2016 
BIX01294 
histone-lysine methyl-  
transferase (HMTase) inhibitor 
Cao et al. 2016 
AS8351 histone demethylase inhibitor Cao et al. 2016 
SC1 
extracellular signal-regulated 
kinase 1 (ERK1) and Ras GTPase-
activating protein (Ras-GAP) 
inhibitor 
Cao et al. 2016 
Y27632 
Rho-associated coiled coil 
formingprotein serine/threonine 
kinase (ROCK) inhibitor 
Cao et al. 2016 
OAC2 epigenetic modulator Cao et al. 2016 
SU16F 
Platelet-derived growth factor 
receptor (PDGFR)-β inhibitor 
Cao et al. 2016 
JNJ10198409 PDGFR-α and PDGFR-β inhibitor Cao et al. 2016 
 
These initial reports with small-molecule compound direct reprogramming seem 
promising; however, more research is needed before any conclusions can be made 
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about therapeutic potential. Finding ways to replace cardiac TF with small-molecule 
compounds in direct cardiac reprogramming has huge implications for future cardiac 
regenerative therapy as it brings direct reprogramming closer to actual therapeutic 
applications. Even though small-molecule compounds decrease the risk of genome 
alteration compared to the use of viral vectors there might be other safety concerns 
associated with the use of small-molecule compounds that need to be thoroughly 
investigated. Furthermore, generation of mature iCMs is also a challenge for 
chemically induced direct cardiac reprogramming (Cao et al. 2016). Unveiling the 
molecular mechanisms underlying direct reprogramming will be important in the 
search for new small-molecule compounds that could induce high efficiency direct 
cardiac reprogramming. 
 
 
3 AIM OF THE STUDY 
 
Even though the reprogramming efficiency of direct cardiac reprogramming has been 
improved by inclusion of additional TFs and optimised reprogramming protocols, the 
efficiency still remains too low for any potential clinical application (Addis and Epstein 
2013). The use of small-molecule compounds in direct cardiac reprogramming has 
previously been shown to increase the reprogramming efficiency (Ifkovits et al. 2014). 
The aim of this M.Sc. thesis work was to establish a small-molecule compound 
screening platform for direct reprogramming of MEFs to iCMs in order to identify new 
small-molecule compounds that together with overexpression of TFs would enhance 
direct cardiac reprogramming. 
 
In order to set up a small-molecule compound screening platform the first goal was to 
be able to successfully directly reprogram MEFs to iCMs and to optimise the 
reprogramming protocol. After being able to successfully reprogram MEFs to iCMs the 
second goal was to set up the small-molecule compound screening platform. The aim 
with the screening platform is to be able to use it to screen for possible candidate 
molecules that could either increase the reprogramming efficiency in addition to TFs or 
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identify small-molecule compounds that could replace the use of TFs altogether. Initial 
tests of the platform were carried out with small-molecule compounds that were 
selected from the literature based on their reported abilities to facilitate direct cardiac 
reprogramming, directed differentiation from stem cells to cardiomyocytes or 
reprogramming of fibroblasts to iPSCs. Also preliminary tests of new molecular entities 
were carried out.  
 
 
4 MATERIALS AND METHODS 
 
4.1 Primary mouse embryonic fibroblasts 
 
Primary MEFs used in this study were derived from E13.5 (embryonic day 13.5) 
embryos of wild type C57BL/6J mice. Mouse embryonic fibroblasts were chosen as the 
source of somatic cells, because of their wide use as a starting cell population for 
direct reprogramming to different targets, including cardiomyocytes. Mouse 
embryonic fibroblasts are easy to maintain and they proliferate rapidly, which also 
makes them an attractive cell model for drug screening experiments. The MEFs used in 
this study were a kind gift from Dr. Maxim Bespalov (University of Helsinki). 
 
4.2 Lentiviral vectors 
 
Lentiviruses are a type of retrovirus that are highly suitable for gene transfer, as they 
can infect both dividing and non dividing cells (Tolmachov et al. 2011). Lentiviruses 
have often been used as gene vectors for direct reprogramming, because of their 
ability to deliver genes with a high efficiency to the nucleus of the target cell, enabeling 
stable transgene expression. The lentiviral vectors used in this study were second 
generation lentiviruses, generated by the Biomedicum Functional Genomics Unit 
(Helsinki, Finland) (Table 4). In second generation lentiviral vectors the lentivirus 
genome is edited to include only genes necessary for virus production and the genes 
are split into three plasmids (a packaging plasmid, an envelope plasmid and a transfer 
 
 
 
41 
 
plasmid) in order to increase bio-safety by reducing the risk of generating replication 
competent lentivirus.   
 
The lentiviral vectors had been packaged in human embryonic kidney (HEK) 293T cells 
(Lenti-X 293T cells, Clontech) by transfecting the cells with the backbone plasmid, 
psPAX2 packaging plasmid (Addgene plasmid 12260) and the pMD2.G envelope 
plasmid (Addgene plasmid 12259). The plasmids had been sequenced prior to viral 
production. The viral titer was determined by measuring the p24 capsid protein 
concentration (pg/ml) from the cell culture supernatant with a p24 specific enzyme-
linked immunosorbent assay (ELISA). Lentiviruses used for all experiments had a 
minimum titer of 105 pg/ml. 
 
Viral vectors consisting of the desired TF open reading frame cloned into a doxycycline-
inducible destination vector (FU-tetO-Gateway) with a Tet-ON promoter were used in 
order to regulate the expression of the transgenes. When combined with the reverse 
tetracycline transactivator (rtTA) –lentiviral vector (FUdeltaGW-rtTA), the expression of 
the TFs could be induced at a chosen time with addition of doxycycline. Each used 
lentivirus contained a single TF. The used TF lentiviral vectors also contained a V5 
epitope tag at the C-terminus for identification with immunostaining. 
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Table 4. Lentiviral vectors used for direct reprogramming and the titers of the virus 
stock determined by p24 capsid protein specific enzyme-linked immunosorbent assay. 
FuGu refers to Biomedicum Functional Genomics unit at the University of Helsinki.  
Construct 
Addgene 
catalog 
numbers 
Virus stock viral 
titer (pg/ml) 
Estimated 
infectious units 
(IFU/ml) 
Producer 
FUdeltaGW-
rtTA 
19780 5.91x105 
5.91x106 – 
5.91x107 
FuGu 
tetO-Hand2 46028 5.87x105 
5.87x106 –  
5.87x107 
FuGu 
tetO-NKX2-5 46029 2.72x105 
2.72x106 –
2.72x107 
FuGu 
tetO-GATA4 46030 7.93x105 
7.93x106 – 
7.93x107 
FuGu 
tetO-MEF2C 46031 1.58x106 
1.58x107 – 
1.58x108 
FuGu 
tetO-TBX5 46032 4.49x105 
4.49x106 –
4.49x107 
FuGu 
TroponinTGCa
MP5-Zeo 
46027 
1.57x105 
1.57x106– 
1.57x107 
FuGu 
 
 
4.3 Candidate small-molecule compounds 
 
Small-molecule compounds were tested for their ability to increase reprogramming 
efficiency or induce Gata4 protein expression. Commercially available small-molecule 
compounds (Sigma-Aldrich, Steinheim, Germany), KY02111 (Xcess Biosciences Inc, CA, 
USA), IWP-4 (Stemgent Inc, MA, USA) and Sodium butyrate (Sigma-Aldrich) were 
selected from the literature based on their reported abilities to facilitate directed 
differentiation from stem cells to cardiomyocytes or reprogramming to iPSCs. In 
addition to commercially available compounds also compounds synthesised at the 
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University 
of Helsinki were tested. These molecules are referred to as 3i-1047, 3i-1103 and 3i-
1070. Molecule I-666 and I-595 were purchased from Pharmatory Ltd (Oulu, Finland). 
All used small-molecule compounds were diluted in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich).  
 
 
 
 
43 
 
4.4 Culturing of primary cells 
 
Primary MEFs were maintained on gelatin-coated culture dishes at 37 °C with 5% 
carbon dioxide (CO2) in a humidified incubator. The cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin (MEF medium). 
Medium was changed every 2-3 days. Primary MEFs (passage 1 or 2) were stored 
frozen at - 150 °C and thawed and grown for 2-3 days prior to passaging. When the 
cells reached approximately 80-90% confluency, they were passaged using trypsin 
TrypLE™ Select Enzyme (Gibco Life Technologies, Paisley, UK) and plated. Cells were 
used at passage 2 or 3 for all reprogramming experiments.  
 
4.5 Optimisation of lentiviral vectors  
 
The FUdeltaGW-rtTA lentiviral vector transduction efficiency was optimised using a 
tetO-GFP reporter lentiviral vector that expresses GFP when combined with the 
FUdeltaGW-rtTA vector. Mouse embryonic fibroblasts were plated on a gelatin-coated 
24-well plate (Corning® Costar®, Corning Inc., Corning, NY, USA) at 15 000 cells / well 
and transduced with different amounts of FUdeltaGW-rtTA and tetO-GFP 
approximately 30 min after plating. Expression of the tetO-GFP vector was induced the 
following day with 2 μg/ml doxycycline (Sigma-Aldrich). The cells were examined by 
fluorescence microscopy (EVOS® FL Cell Imaging System, Thermo Fisher Scientific Inc., 
Rockford, IL, USA) for GFP expression 48 hours after induction. 
 
For optimisation of transduction of TF lentivirus, MEFs were plated on a gelatin-coated 
24-well plate (Corning® Costar®) at 15 000 cells / well. The cells were transduced with 
FUdeltaGW-rtTA (50 µl / well) 24 hours after plating and after another 24 hours the 
cells were transduced with 25 µl or 100 µl of one of the TF lentiviruses. Each of the 5 
TF vectors (tetO-Hand2, tetO-NKX2.5, tetO-GATA4, tetO-MEF2C, and tetO-TBX5) were 
tested. Expression of the tetO-TF lentiviral vectors were induced the following day with 
2 μg/ml doxycycline. The cells were stained for V5 expression two days after induction. 
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To optimise the transduction efficiency of the TroponinT-GCaMP5-Zeo reporter 
lentivirus, mouse atrial embryonic cardiomyocytes (harvested from E14.5 embryos) on 
a 12-well plate (cell dencity could not be counted due to poor dissociation), were 
transduced with 250 µl of virus. The cells were observed with fluorescence microscopy 
(EVOS® FL Cell Imaging System) 2-3 days after transduction for detection of GCaMP 
activity. The cells were kindly provided by Robert Leigh (University of Helsinki). 
 
4.6 Direct reprogramming of mouse embryonic fibroblasts to induced cardiomyocytes 
 
Direct reprogramming of MEFs to cardiomyocytes was performed by overexpressing 
cardiac TFs Hand2, NKX2.5, GATA4, MEF2c, and TBX5 (HNGMT). The experiments were 
carried out using an adaptation of a protocol originally published by Ifkovits et al. 
2014. The protocol was optimised by modifying various conditions, such as culture 
medium, plating substrate, viral vector concentrations, time of transduction and cell 
density. An outline of the final protocol is shown in figure 5.  
 
The first reprogramming experiments were carried out using a Troponin T-GCaMP 
reporter system, identical to the one used by Ifkovits et al. (2014), as a functional 
outcome measure. In the Troponin T-GCaMP reporter system the expression of the 
calcium indicator GCaMP5 is driven by a cardiomyocyte-specific Troponin T promoter. 
The GCaMP5 protein contains a calcium-binding calmodulin domain, which is fused to 
GFP. When the intracellular calcium level is high and calcium is bound to the 
calmodulin domain, GFP is expressed resulting in bright fluorescence. In our 
experiments, however, the GFP flashing generated by calcium oscillation in 
cardiomyocytes was not detectable with the available microscope (EVOS® FL Cell 
Imaging System). Due to this, immunocytochemical analysis with cardiac Troponin T 
(cTnT) was used as readout instead.  
 
The final reprogramming experiments were carried out either in a flat-bottomed 24-
well plate (Corning® Costar®) or black-bottomed 96-well ViewPlate® microplate 
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(PerkinElmer Inc., MA, USA). At Day -2 the plates were coated with poly-L-Lysine 
solution (Sigma-Aldrich,) and incubated in room temperature for one hour, after which 
they were washed with phosphate-buffered saline (PBS) and left to dry for a minimum 
of 2 hours. Mouse embryonic fibroblasts (passage 3) were then plated at 15 000 
cells/well for the 24-well plate or 2500 cells/well for the 96-well plate together with 
FUdeltaGW-rtTA lentiviral vector (50 µl/well or 8,4µl/well) and MEF medium so that 
the total volume of each well was 750 μl (24-well plate) or 120 µl (96-well plate). The 
MEF medium was supplemented with 8 μg/ml of Polybrene® (hexadimethrine 
bromide, Sigma-Aldrich, Steinheim, Germany) to increase the transduction efficiency. 
On Day -1 cell culture medium was changed to fresh MEF medium with Polybrene® 
and cells were transduced with each tetO-TF lentivirus (25 µl/well in 24-well plate or 
4,2 µl/well in 96-well plate of each TF expression virus). In experiments testing small-
molecule compounds, also compounds and vehicle control (DMSO) were added on day 
-1. Expression of the doxycycline-inducible tetO-TF lentiviral vectors were induced on 
Day 0 by changing the medium to reprogramming medium consisting of astrocyte 
growth media without epidermal growth factor (AGM, CC-3186, Lonza, Walkersville, 
MA, USA) and supplemented with 2 μg/ml doxycycline. Reprogramming medium was 
changed every 2 days. When testing candidate small-molecule compounds, fresh 
small-molecule compounds and control vehicles were added with every medium 
change. The cells were kept in culture for 2-4 weeks after induction. 
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Figure 5. A schematic illustration of the final direct reprogramming protocol. Mouse 
embryonic fibroblasts (MEFs) were transduced with a reverse tetracycline 
transactivator (rtTA) -lentiviral vector at Day -2. After 24 h (Day -1) the cells were 
transduced with transcription factor (TF) lentiviral vectors with a Tet-ON promoter 
(tetO-TFs). Expression of transcription factors was induced with doxycycline the 
following day (Day 0). Medium was changed every 2-3 days. When testing candidate 
small molecules, cells were first treated with small molecules at Day -1 and fresh small 
molecules were added with every medium change. The cells were kept growing until 
Day 14 or 21 post-induction, when they were fixed analysed with immunostaining for 
cardiac Troponin T (cTnT). 
 
4.7 Immunocytochemistry 
 
For immunocytochemical staining, cells from reprogramming experiments were fixed 
with 4% paraformaldehyde (PFA) for 15 minutes at room temperature and rinsed with 
PBS. The plates were then either stored at + 4 °C or used immediately for 
immunocytochemistry.  
 
The fixed cells were permeabilised with 0,5% Triton X-100 diluted in PBS for 15 
minutes at room temperature. To reduce nonspecific antibody binding, the cells were 
then incubated in Lab Vision™ Ultra V Block- protein block solution (Thermo Fisher 
Scientific) for 10 minutes before adding the primary antibody (table 5). The cells were 
incubated in 250 µl primary antibody (1:200 or 1:500, diluted in 3% bovine serum 
albumin, BSA in PBS) overnight, rocking at + 4 °C. The following day the cells were 
washed 6 times for 10 minutes with PBS and then incubated in secondary antibody 
dilution (1:500, diluted in 3% BSA in PBS) for 1 hour in the dark at room temperature. 
After incubation in secondary antibody, the cells were washed 3 times for 5 minutes 
 
 
 
47 
 
with PBS and finally mounted in VectashieldTM mounting media (Vector Laboratories 
Inc., Burlingame, CA, USA) containing 4',6-diamidino-2-phenylindole (DAPI) for nuclear 
staining and examined by fluorescence microscopy (EVOS® FL Cell Imaging System) and 
CellInsight™ high content imaging system (Thermo Scientific). The used secondary 
antibodies are listed in table 6. 
 
Table 5. Primary Antibodies used for immunocytochemistry. Ig = immunoglobulin.  
Antibody Manufacturer Code Description Dilution 
anti-V5 Life technologies R960-
25 
mouse monoclonal 
IgG2ak 
1:200 
anti-cardiac Troponin 
T 
Thermo Scientific MS-
295-P 
mouse monoclonal 
IgG1 
1:200 
anti-GATA4 Santa Cruz 
biotechnology 
SC-1237 goat polyclonal IgG 1:200 
anti-Myl2 Santa Cruz 
biotechnology 
SC-
34490 
goat polyclonal IgG 1:150 
anti-Alpha smooth 
muscle actin 
Sigma-Aldrich A2547 mouse monoclonal 
IgG2a 
1:200 
anti-Thy-1  
 
Santa Cruz 
Biotechnology 
SC-9163 
 
rabbit polyclonal 
IgG 
1:200 
 
Table 6. Alexa Fluor® Secondary Antibodies used for immunocytochemistry.  
Ig = immunoglobulin. 
Antibody Manufacturer Code Description Dilution 
Alexa Fluor® 488 Life Technologies A11055 Donkey Anti-goat 
IgG, green 
1:500 
Alexa Fluor® 488 Life Technologies A21202 Donkey Anti-
mouse IgG, green 
1:500 
Alexa Fluor® 594 Life Technologies A21207 Donkey Anti-rabbit 
IgG 
1:500 
Alexa Fluor® 488 Life Technologies A21206 Donkey Anti-rabbit 
IgG 
1:500 
Bdm 647  Santa Cruz 
Biotechnology 
SC-
362286 
Bovine anti-mouse 
IgG-CFL 647 
1:200 
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4.8 Cell imaging and quantification of induced cardiomyocytes  
 
Cells were observed every 1-2 days during the whole direct reprogramming process 
using light microscopy (Leica DM IL LED, Leica Microsystems, Wetzlar, Germany) for 
changes in cell morphology, signs of cell toxicity and for spontaneously beating cells. 
For quantification of iCMs after immunostaining for cTnT, cells were imaged with 
fluorescence microscopy (EVOS® FL Cell Imaging System,). Pictures were taken of 4 
unique fields of view (4 x magnification) in a single well and cells were counted with 
the cell counter plugin in ImageJ software. Reprogramming efficiency was assessed by 
comparing the number of cTnT+ cells to the total number of cells stained with DAPI. A 
minimum of 500 total cells were counted per condition for reprogramming 
experiments carried out with the optimised protocol. Values are expressed as mean ± 
standard deviation (SD). Statistical analysis was not preformed due to lack of replicates 
in different experiments. 
 
 
5 RESULTS 
 
5.1 Preliminary experiments to evaluate lentiviral vectors  
 
The first goal towards direct reprogramming of MEFs to iCMs was to optimise the 
transduction efficiency of the lentiviral vectors in order to ensure overexpression of 
the desired TFs. The p24 capsid protein concentration (pg/ml) of the virus stock can 
only be used to estimate the amount of functional virus in the stock (IFU/ml). In order 
to ensure high enough levels of expression of the TFs, the viral vectors were tested and 
the transduction efficiency determined. Also the TroponinT-GCaMP5-Zeo lentiviral 
vector was tested to ensure that the readout of the experiments was valid and reliable. 
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5.1.1 Optimisation of transduction efficiency of the FUdeltaGW-rtTA vector 
 
Since the FUdeltaGW-rtTA vector is required for Tet-on regulated activation of the 
transgene expression, it works as a limiting factor for transduction efficiency. Using 
enough FUdeltaGW-rtTA vector was therefore critical for the reprogramming 
experiments. The optimal amount of FUdeltaGW-rtTA was determined by transducing 
MEFs with 20 µl, 50 µl and 100 µl of the FUdeltaGW-rtTA and with a tetO-GFP lentiviral 
vector. The tetO-GFP lentiviral vector was also used to test the FUdeltaGW-rtTA 
construct, as seeing GFP expression from the tetO promoter when FUdeltaGW-rtTA 
virus is included suggests that the construct is working as it should. 
 
The transduction efficiency was assessed two days post-induction by comparing the 
number of cells expressing GFP to the total number of cells stained with DAPI (Figure 
6). The highest transduction efficiency was achieved with 100 µl of the rtTA viral 
vector, which resulted in a transduction efficiency of 97%, while 50 µl viral vector 
resulted in an efficiency of 94% and 20 µl in 81%. However, the difference between the 
transduction efficiency gained with 50 µl and 100 µl was so small that based on these 
results it was decided to use 50 µl FUdeltaGW-rtTA virus for the reprogramming 
experiments.  
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Figure 6. Optimisation of transduction efficiency of FUdeltaGW-rtTA viral vector. 
Transduction efficiency was evaluated at Day 2 post induction using a green 
fluorescent protein (GFP) marker vector with a with a Tet-ON promoter that expresses 
GFP when combined with the FUdeltaGW-rtTA vector (n=1). The transduction 
efficiency was quantified the using cell counter plugin in ImageJ software. Scale bar is 
1000 µm. DAPI = 4',6-diamidino-2-phenylindole. 
 
5.1.2 Optimisation of transduction efficiency of transcription factor viral vectors 
 
Viral transduction efficiency and overexpression of TFs was evaluated for MEFs 
transduced with TF viral vectors at Day 2 post-induction, using immunostaining for the 
V5 epitope tag at the C-terminus of the vectors containing the TFs. The viral 
transduction efficiency was evaluated for each TF separately and for all 5 TFs (HNGMT) 
together (Figure 7). All TF vectors had a transduction efficiency over 70%. The joint 
viral transduction efficiency for all 5 TF vectors was determined to be 84%. It is 
however to be noted that the joint viral transduction efficiency only means that that 
the cells got at least one TF and the percentage of cells that received all five TFs is not 
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known. The transduction efficiency of the tetO-Hand2 viral vector could not be 
determined due to a stop codon located in the vector backbone before the C-terminus. 
 
 
Figure 7. Determination of viral transduction efficiency. Transduction efficiency was 
evaluated at Day 2 post induction using immunostaining for the V5 epitope tag at the 
C-terminus of the transcription factor viral vectors. The joint viral transduction 
efficiency for all 5 transcription factor vectors was determined to be 84% (n=1). The 
transduction efficiency is expressed as the percentage of V5+ quantified using cell 
counter plugin in ImageJ software. Scale bar is 400 µm. DAPI = 4',6-diamidino-2-
phenylindole. 
 
5.1.3 Optimisation of transduction efficiency of the TroponinT-GCaMP5-Zeo reporter 
lentivirus 
 
The transduction efficiency of the TroponinT-GCaMP5-Zeo reporter lentivirus was 
tested and optimised by transducing mouse atrial embryonic cardiomyocytes with the 
reporter vector (TroponinT-GCaMP5-Zeo). TheCaMP5 activity in the cells was observed 
with fluorescence microscopy 2-3 days after transduction. As previously described, 
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calcium oscillations in beating cardiomyocytes transfected with the reporter vector 
should result in green fluorescent flashing (Addis et al. 2013). When observing the cells 
with fluorescence microscopy, clusters of robust beating cells were clearly visible and 
they expressed GFP (figure 8). However, no GFP flashing was seen, even though the 
cells were beating. Due to these observations, the conclusion was made that GFP 
flashing could not be seen with the available microscope. Based on this, the decision 
was made to change the readout to immunocytochemical analysis for cTnT, in order to 
get a quantifiable readout. 
 
 
Figure 8. Validation of the TroponinT-GCaMP5-Zeo reporter lentiviral vector in mouse 
atrial embryonic cardiomyocytes. Robustly beating clusters of cardiomyocytes 
expressed green fluorescent protein (GFP) at Day 3 post transduction, but no GFP 
flashing was observed. A.) Beating cluster of mouse atrial embryonic cardiomyocytes. 
B.) GFP is expressed in beating cardiomyocytes. Scale bar is 200 µm. 
 
5.2 Optimisation of the reprogramming protocol 
 
It has been suggested that seemingly small differences in the direct reprogramming 
experimental procedures, such as culture medium, plating substrate, cell density and 
viral titers, may be behind the varying and inconsistent reprogramming efficiencies 
reported by different groups (Addis and Eppstein, 2013). In order to find the optimal 
conditions for the direct reprogramming experiments, different conditions in the 
protocol were changed to observe which conditions resulted in the highest 
reprogramming efficiency. Also different lengths of cell culture times were tested 
B A 
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during the optimisation process. This was done to find out if longer culture time would 
have a positive effect on the reprogramming. 
 
5.2.1 Determining optimal amount of of transcription factor vectors 
 
As described earlier, the p24 capsid protein concentration only gives an estimate of 
the functional virus in the viral vector stock. Therefore, specific concentrations of virus 
stock could not be used for the experiments, as the exact concentration of infectious 
units in the virus stocks could not be calculated. Instead MEFs were transduced with 
different amounts of the HNGMT viral vectors (25 µl, 50 µl, 75 µl and 100 µl of each TF 
viral vector) to see which amount resulted in the highest reprogramming efficiency. 
Upon quantification at Day 32, the highest reprogramming efficiency was achieved 
with 25 µl of each HNGMT virus, which generated 5,20% iCMs (Figure 9). The 
reprogramming efficiency as well as the total cell number decreased with an increasing 
amount of virus. Treatment with 50 µl of each HNGMT viral vectors generated 4,56% 
iCMs, while 75 µl only generated iCMs with an efficiency of 1,47%. With 100 µl of each 
HNGMT viral vectors the cell death was so extensive that no quantification could be 
done. 
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Figure 9. Determination of the optimal amount of transcription factor viral vector for 
direct reprogramming. Mouse embryonic fibroblasts (MEFs) were transduced with 
different amounts of viral vectors (25 µl, 50 µl and 75 µl of each transcription factor 
vector) and the transduction efficiency was assessed 32 days after induction using 
immunostaining for cardiac troponin T. The highest transduction efficiency was 
achieved with 25 µl of each virus (n=1). 
 
Next the effect of TF stoichiometry on reprogramming efficiency was examined. Based 
on observations during previous experiments, NKX2.5, TBX5 and Hand2 seemed to be 
more toxic to the cells than MEF2C and GATA4. Since the previous experiments also 
showed that higher viral toxicity resulted in lower reprogramming efficiency, it was 
examined if lower expression levels of NKX2.5, TBX5 and Hand2 had a positive effect 
on reprogramming efficiency. Also, according to a recent publication by Wang et al. 
(2015), optimal stoichiometry of Gata4, Mef2c and Tbx5 has a great influence on 
reprogramming efficiency and on the expression of mature cardiac genes in iCMs. 
Their study showed that vectors that expressed higher levels of Mef2c and lower levels 
of Gata4 and Tbx5 resulted in a higher reprogramming efficiency compared to the 
other vectors. 
 
Based on these results 6 different conditions were selected and their effect on the 
reprogramming efficiency was compared: 10 µl of each TF viral vector (HNGMT), 10 µl 
H: Hand2 
N: Nkx2.5 
G: Gata4 
M: Mef2c 
T: Tbx5 
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of each HNGT viral vector + 100 µl of M, 100 µl of G and M + 10 µl of each HNT viral 
vector, 100 µl of each HNT viral vector + 10 µl of G and M, 25 µl of each HNGMT viral 
vector and 50 µl of each HNGMT viral vector. The results are shown in figure 10. The 
combination consisting of 10 µl of each HNGT + 100 µl of M (0,18%) did not result in a 
higher reprogramming efficiency compared to the other conditions. An increase in the 
reprogramming efficiency was, however, observed with higher levels of G and M (10 µl 
of each HNT + 100 µl of G and M, 1,03%) when compared with 10 µl of each HNGT + 
100 µl of M (0,18%) and 100 µl of each HNT + 10 µl of G and M (0,04%). The highest 
reprogramming efficiency was still achieved with 25 µl of each HNGMT TF (1,90%). 
Based on these results it was decided to use 25 µl of each HNGMT TF for the 
reprogramming experiments. It is to be noted that these results are based on single 
experiments and therefore no conclusions on the effect of HNGMT stoichiometry on 
reprogramming efficiency can be drawn from on these results. 
 
Figure 10. The effect of transcription factor stoichiometry on reprogramming 
efficiency. Mouse embryonic fibroblasts (MEFs) were transduced with different 
amounts of HNGMT viral vectors and the transduction efficiency was assessed 26 days 
after induction with immunostaining for cardiac troponin T (cTnT) (n=1). The 
reprogramming efficiency is expressed as the percentage of cTnT+ cells analysed with 
immunostaining and quantified using cell counter plugin in ImageJ software. 
 
H: Hand2        n=1 
N: Nkx2.5 
G: Gata4 
M: Mef2c 
T: Tbx5 
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5.2.2 Determining optimal culture conditions 
 
During the optimisation of the protocol, culture conditions were changed 
systematically in order to find the optimal conditions for the direct reprogramming 
experiments. The parameters to optimise were cell culture medium, plating substrate, 
cell density and culturing times. 
 
In the direct reprogramming protocol developed by Ifkovits et al. (2014) they used 
AGM without epidermal growth factor for their reprogramming experiments. In order 
to see if the same results could be achieved using MEF medium, the effects of these 
two culture mediums on reprogramming efficiency were compared. The 
reprogramming efficiency gained using AGM (3,8 %) was notably higher than the 
efficiency in MEF medium (<0,01%). Therefore, AGM was selected for the future 
reprogramming experiments. 
 
The choice of plating substrate affects the attachment, growth pattern and number of 
the cells and can thus have an indirect effect on direct reprogramming. In order to get 
clear and quantifiable data, effect of gelatin and poly-L-lysine as plating substrates on 
reprogramming efficiency was compared. Mouse embryonic fibroblasts plated on 
either gelatin- or poly-L-lysine coated wells were transduced with the TF GATA4 and 
the transduction efficiency was determined with anti-Gata4 immunostaining at Day 4 
post-induction. Both transduction efficiency and total cell number were higher with 
poly-L-lysine than with gelatin (data not shown). Even though the difference between 
the two plating substrates was not great, it was decided to use poly-L-lysine for future 
experiments, as the cells were higher in number and looked more viable. 
 
The initial experiments showed that treatment with the viral vectors was toxic for the 
cells and the number of surviving cells after 2-4 weeks in culture was low.  Therefore, it 
was examined if a higher cell density (25 000 cells/well) at plating would have a 
positive effect on the cell survival and the reprogramming efficiency. The experiments 
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however showed that even though higher initial cell density at plating resulted in a 
higher number of surviving cells, the reprogramming efficiency was not greatly 
influenced by this (data not shown). 
 
Finally, it was examined if a longer culture time resulted in a higher reprogramming 
efficiency. The culturing times for the different experiments were varied between 2-4 
weeks. Longer culturing times were found to seemingly result in higher reprogramming 
efficiencies and more mature cardiomyocytes, as indicated by higher number of 
beating cells and cells with visible sarcomere structure (data not shown). Longer cell 
culturing times did however also result in fewer total number of cells at the time of 
quantification (data not shown). Individual experiments, even though executed 
following the same protocol, resulted in very varying reprogramming efficiencies. 
 
5.3  Immunocytochemical analysis of induced cardiomyocytes 
 
Immunocytochemical analysis of HNGMT-transduced MEFs revealed expression of the 
cardiac specific marker cTnT. The percentage of cells expressing cTnT varied with each 
experiment. Representative images of iCMs stained for cTnT are shown in figure 11. 
While some iCMs had clearly organised sarcomeres and a cardiomyocyte-like rod 
shaped morphology, the majority of cells expressing cTnT did not have organised 
sarcomeres and the morphologies of these cells were varying and irregular. Non-
transfected cells and cells transfected with only FUdeltaGW-rtTA lentivirus were used 
as controls to rule out the possibility that cTnT protein expression would be caused by 
components of the medium or cytokines. No cTnT expression was detected in cells that 
were not transduced with TF lentiviruses (figure 12). Some cell batches transduced 
with HNGMT did not express cTnT at all. These experiments were defined as failed and 
the results are not included in analyses. 
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Figure 11. Representative immunofluorescence images of Day 14 HNGMT (Hand2, 
NKX2.5, GATA4, MEF2C and TBX5) -induced cardiomyocytes (iCMs) stained for cardiac 
troponin T (cTnT) (green) and 4',6-diamidino-2-phenylindole (DAPI) (blue). Images A-D 
show iCMs with different levels of sarcomere assembly indicating different levels of 
maturation of iCMs. In A-B no sarcomere formation is seen and the cell morphology is 
highly irregular. In C sarcomere structure is starting to organise and D represents a 
more mature iCM with a rod-shaped morphology and well organised sarcomeres. The 
region in the white box is enlarged to show sarcomere structure. All types were 
commonly observed in the reprogramming experiments. Scale bars are 200 µm. 
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Figure 12. Representative immunofluorescence images of reverse tetracycline 
transactivator (rtTA) –lentiviral vector only control compared with HNGMT-transduced 
mouse embryonic fibroblasts (MEFs) at Day 14 post-induction stained for cardiac 
troponin T (cTnT) (green) and 4',6-diamidino-2-phenylindole (DAPI) (blue). MEFs that 
were not transduced with transcription factor lentiviruses did not stain positive for 
cTnT. Scale bar is 1000 µm. H = Hand2, N= NKX2.5, G = GATA4, M = MEF2C, T = TBX5.  
 
The cells were also analysed for expression of the smooth-muscle cell marker α-
smooth muscle actin (α-SMA). The expression of α-SMA in the cells was analysed, as it 
is a marker of immature cardiomyocytes and normally expressed in early stages of 
cardiomyocyte differentiation. α-SMA is however not a specific cardiomyocyte marker 
and it is also expressed in other smooth muscle cells and in myofibroblasts. 
Immunocytochemical analysis reveald α-SMA expression in both HNGMT-transduced 
MEFs and in the control with only FUdeltaGW-rtTA-lentivirus (Figure 13). Upon 
quantification at Day 21 post-induction approximately 41,2% of the HNGMT-
transduced cells and 21,9% of the control without TF lentiviruses expressed α-SMA (N 
= 1, data not shown). Fibroblasts are known to start expressing α-SMA in cell culture as 
 
 
 
60 
 
they transdifferentiate into myofibroblasts, which is most likely the cause of α-SMA 
expression the control cells and in most HNGMT-transduced cells. 
 
 
Figure 13. Representative immunofluorescence images of Day 21 HNGMT (Hand2, 
NKX2.5, GATA4, MEF2C and TBX5)-transduced mouse embryonic fibroblasts and 
control stained for α-smooth muscle actin (α-SMA) (red) and 4',6-diamidino-2-
phenylindole (DAPI) (blue). Scale bar is 1000 µm.  
 
5.4 Beating induced cardiomyocytes 
 
All reprogramming experiments were qualitatively observed with light microscope 
every 1-2 days during the whole direct reprogramming process in order to find 
spontaneously beating cardiomyocytes. Sporadic single beating cells were seen in 
HNGMT-transduced iCMs as early as Day 13 post-induction (shown in supplemental 
movie 1). Beating cells were however not observed in all experiments. The occurrence 
of beating cells during the direct reprogramming process also seemed to correlate with 
a higher reprogramming efficiency when the cells were analysed with 
immunocytostaining. This was however not quantified.  
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5.5 Candidate small-molecule compound testing 
 
5.5.1 Small-molecule compound testing in direct cardiac reprogramming 
 
After being able to successfully convert MEFs to iCMs the next step was to test out the 
screening platform. For initial testing of the screening platform the TGF-β inhibitor 
SB431542 (SB) and histone deacetylase inhibitor sodium butyrate were selected. SB 
has previously been shown to increase the reprogramming efficiency of HNGMT-
transduced MEFs up to 5-fold compared with baseline condition of HNGMT+DMSO 
(Ifkovits et al. 2014). Sodium byturate was selected based on its ability to increase the 
efficiency of iPSC derivation from fibroblasts (Mali et al. 2010). Upon quantification at 
Day 26, the baseline condition (HNGMT+DMSO) generated iCMs with an efficiency of 
0,50% (figure 14). Treatment with 0,5 µM SB increased the reprogramming efficiency 
to 3,21% and treatment with 2 µM SB to 5,86%. Sodium butyrate on the other hand 
decreased the reprogramming efficiency with both 0,25 µM (0,01%) and 1 µM (0,04%). 
Also a decrease in the total cell number was observed with sodium butyrate. Even 
though the reprogramming efficiencies were low in this experiment, SB increased the 
reprogramming efficiency compared with baseline. This is in line with previous 
publications (Ifkovits e. 2014). 
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Figure 14. Initial testing of the small-molecule compound screening platform with 
small-molecule compound treatment. Mouse embryonic fibroblasts (MEFs) were 
transduced with HNGMT (Hand2, NKX2.5, GATA4, MEF2C, and TBX5) transcription 
factor combination and SB431542 (SB) (0,5 µM and 2 µM) and/or Sodium butyrate 
(0,25 µM and 1 µM) The small-molecule compounds were added 1 day before inducing 
the transcription factor expression and maintained in culture during the whole 
experiment. The cells were fixed at Day 26 and analysed with immunostaining for 
cardiac troponin T (cTnT) (n=1). The reprogramming efficiency is expressed as the 
percentage of cTnT+ cells analysed with immunostaining and quantified using cell 
counter plugin in ImageJ software.  
 
Next the effect of small-molecule compounds on the reprogramming efficiency was 
evaluated using two different TF combinations: HNGMT and HGMT. Addison et al. 
(2013) found that the addition of Nkx2.5 to the HGMT TF combination increases the 
reprogramming efficiency. However, previous publications have reported a decrease in 
the cardiac reprogramming efficiency with the addition of Nkx2.5 in screens for TF 
combinations (Ieda et al. 2010, Song et al. 2012). 
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For this experiment four small-molecule compounds were selected. SB was chosen as 
the baseline in order to obtain enough iCMs, as previous experiments had shown that 
iCMs were not generated consistently without SB. The Wnt signalling pathway is one 
of the major signalling cascades involved in cardiac muscle development and it has 
been shown to have a biphasic role in cardiac development (Sahara et al. 2015). 
Therefore both a Wnt signalling agonist CHIR99021 and a Wnt inhibitor IWP-4 were 
selected for testing. Also two small-molecule compounds, 3i-666 and 3i-595 that are 
targeted to modulate the activity of cardiac TFs were selected.   
 
Upon quantification on Day 21, the control conditions HNGMT + DMSO produced 6,4 ± 
2,9% (n=2, mean ± SD) iCMs and HGMT + DMSO produced 5,3 ± 1,3% (n=2) iCMs 
(figure 15, Figure 16). Consistent with the previous results, an increase in the 
reprogramming efficiency was observed with 2 µM SB treatment in both HNGMT (14,o 
± 6,1%, n=3) and HGMT-transduced cells (13,1 ± 1,3, n=3). Also an increase in 
spontaneously beating iCMs was qualitatively observed with SB treatment in both 
HNGMT and HGMT conditions (data not shown). None of the other small-molecule 
compounds had a positive effect on the reprogramming efficiency. Treatment with 5 
µM I-666 together with 2 µM SB decreased the iCM yield for both HNGMT-transduced 
cells (8,5 ± 1,8%, n=3) and HGMT-transduced cells (8,8 ± 1,7%, n=3). A decrease in the 
reprogramming efficiency and in the total number of cells was also observed with 1,2 
µM IWP-4 treatment in both HNGMT-transduced cells (2,1 %, n=1) and HGMT-
transduced cells (1,5 ± 0,1%, n=2). Addition of 2 µM SB to the IWP-4 treatment 
increased the reprogramming efficiency for both HNGMT (5,3 ± 2,3%, n=2) and HGMT 
(6,6 ± 2,5%, n=2), but the yield was still lower than for SB alone. Treatment with 
CHIR99021 and I-595 was so toxic to the cells that no results could be obtained for 
these compounds. A minimum of 500 total cells were analysed for each condition / 
experiment. 
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Figure 15. Representative immunocytochemistry images for HGMT- and HNGMT-
induced cardiomyocytes (iCMS) treated with small-molecule compounds. Small-
molecule compounds were added one day before inducing the transcription factor 
expression and maintained in culture during the whole experiment. The cells were 
fixed and stained for cardiac troponin T (red) and 4',6-diamidino-2-phenylindole (DAPI) 
(blue) at Day 21 post-induction. Scale bar is 1000 µm. SB = SB431542, H = Hand2, N= 
NKX2.5, G = GATA4, M = MEF2C, T = TBX5.  
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Figure 16. Comparison of the effect of small-molecule compounds on reprogramming 
efficiency for HGMT- and HNGMT-transduced mouse embryonic fibroblasts. Mouse 
embryonic fibroblasts were transduced with either HGMT or HNGMT transcription 
factor combination and treated with DMSO (n=3), SB431542 (SB) (n=3), IWP-4 (HGMT 
n=2, HNGMT n=1), SB + I-666 (n=3) or SB + IWP-4 (n=2). The reprogramming efficiency 
was assessed at Day 21. The reprogramming efficiency is expressed as the percentage 
of cTnT+ cells analysed with immunostaining and quantified using cell counter plugin in 
ImageJ software. Values are expressed as mean ± standard deviation (SD). H = Hand2, 
N= NKX2.5, G = GATA4, M = MEF2C, T = TBX5.  
 
5.5.2 Gata4 protein induction with small-molecule compounds 
 
In addition to screening for small-molecule compounds that would enhance direct 
cardiac reprogramming, compounds were also tested for their ability to induce Gata4 
protein expression in MEFs. For this four small-molecule compounds were selected: I-
666, 3i-1047, 3i-1103 and 3i-1070. These molecules are targeted to modulate the 
activity of cardiac TFs. Mouse embryonic fibroblasts were exposed to 1 µM, 3 µM, 5µM 
and 10 µM of I-666, 3i-1047, 3i-1103 or 3i-1070 24 hours after plating and the small-
molecule compounds were maintained in culture during the whole experiment. Mouse 
embryonic fibroblasts transduced with tetO-GATA4 lentivirus were used as a positive 
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control and medium only and vehicle only (MEF medium containing 0.1% DMSO) were 
also were used as a negative control. After 14 days in culture, the cells were fixed and 
analysed with immunostaining for Gata4. The stained cells were imaged for Gata4 
protein expression, but no expression of Gata4 protein was observed for any of the 
four small-molecule compounds (data not shown). 
 
 
6 DISCUSSION 
 
Small-molecule compounds have been suggested to be a potential solution in 
overcoming some of the major challenges involved in direct reprogramming. The 
results of this M.Sc. thesis work demonstrate a method for in vitro small-molecule 
compound screening that can be used to identify compounds that increase the 
reprogramming efficiency in direct cardiac reprogramming. The aim is to in the future 
be able to use small-molecule compounds to achieve direct cardiac reprogramming as 
a regenerative therapy for MI and HF. 
 
A great part of setting up the screening platform consisted of finding the optimal 
conditions for direct reprogramming of MEFs to iCMs. Previous research has shown 
great variation in the reported results of direct cardiac reprogramming. A possible 
explanation can be found in different experimental procedures and protocols, as 
seemingly small differences in protocols might influence the reprogramming efficiency  
(Addis and Epstein 2013). Several different parameters were optimised, including cell 
density, medium, plating substrate and culturing times. None of the parameters alone 
resulted in notable increases of reprogramming efficacy, but in total the optimisation 
of protocol produced a reprogramming efficiency of 6,44 ± 2,92% (n=2) (HNGMT + 
DMSO).  
 
The reprogramming efficiency achieved after optimisation of the protocol is in line 
with previous research by Ifkovits et al. (2014), who reported a reprogramming 
efficiency of 4,96 ± 1,80% using the same TF combination. When comparing these 
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results to other publications it is however important to note that the differences in 
starting cell population, used TF combinations, outcome measures and evaluated time 
points affect the reprogramming efficiency and the results might not be comparable 
with each other. In this study immunocytochemical analysis of cTnT expression was 
used as a read out measure. Compared to the functional Troponin T-GCaMP reporter 
used by Ifkovits et al., measuring cTnT protein expression is a less stringent method as 
it only measures the expression of a single protein, which usually gives a higher 
reprogramming efficiency. The achieved reprogramming efficiencies in this study could 
therefore have been expected to be higher, as Ifkovits et al. (2014) achieved a similar 
reprogramming efficiency using the same viral constructs, but with a more stringent 
outcome measure.  
 
High enough expression levels of cardiac TFs is crucial for successful direct 
reprogramming. Chen et al. (2012) were unable to directly reprogram mouse TTFs and 
CFs by lentiviral overexpression of the GMT TF combination. It has been suggested that 
the lentiviral vectors used by Chen et al. could not express GMT at high enough levels 
(Addis and Epstein 2013). Prior to starting the reprogramming experiments the 
transduction efficiencies of the lentiviral vectors used in this study were optimised and 
the transduction efficiency was determined. Even though high enough transduction 
efficiencies were achieved for NKX2.5, GATA4, MEF2C and TBX5 the transduction 
efficiency for Hand2 could not be determined and it can therefore not be confirmed 
that the cells expressed high enough levels of Hand2. As the TFs were delivered with 
separate vectors for each TF the amount of cells that expressed all five TFs could also 
not be confirmed. It is possible that the total transduction efficiency remained too low, 
which might explain the low reprogramming efficiencies. However, the constructs used 
in this study were identical to the ones used by Ifkowits et al. (2014) , who achieved a 
reprogramming efficiency of 5% at baseline using the same separate vector delivery 
strategy.  
 
 
 
 
68 
 
Optimal TF stoichiometry has also been reported to influence the efficiency and quality 
of direct cardiac reprogramming. Wang et al. (2015) showed that higher expression 
levels of Mef2c and lower levels of Gata4 and Tbx5 resulted in a higher reprogramming 
efficiency. Unlike what was expected, higher levels of MEF2C did not result in a higher 
reprogramming efficiency compared to the other conditions. Instead the highest 
reprogramming efficiency was achieved with equal volumes of all five TFs (HNGMT). 
However, when examining these results, it needs to be noted that the viral vector 
stocks used in this study all had different viral titers and all TFs were delivered on 
separate vectors leading to heterogenous and uncontrolled ratios of TF expression. 
The MEF2C viral vector stock had the highest viral titer and therefore when giving cells 
equal volumes of TF lentiviral vectors the achieved expression level of MEF2C was 
probably higher than the expression levels of the other factors. However, capsid-based 
titering is very unreliable and can only be used to estimate the viral titer so the the real 
infectious units are unknown. Also, a possible explanation to the difference in our 
results is that Wang et al. (2015) used the GMT TF combination and the effect of 
Nkx2.5 and Hand2 stoichiometry on direct cardiac reprogramming has not been 
studied before. 
 
The second phase of this thesis consisted of examining the effects of a set of small-
molecule compounds on the reprogramming efficiency. An initial set of compounds 
were selected based on their reported abilities to facilitate direct cardiac 
reprogramming, directed differentiation from stem cells to cardiomyocytes or 
reprogramming of fibroblasts to iPSCs. Of the tested molecules only the TGF-β 
inhibitor SB induced a clear increase on reprogramming efficiency The reprogramming 
efficiency increased over 2-fold when compared with control. SB has previously been 
reported to increase the reprogramming efficiency over 5-fold (Ifkovits et al. 2014). 
Even though the results here were in line with previous publications, they also 
demonstrate the great variability in results by different groups.  
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The TGF-β superfamily consists of a large number of growth factors that regulate 
several cellular functions, including proliferation and differentiation (Inman et al. 
2002). SB is a specific inhibitor of the TGF-β superfamily type I activin receptor-like 
kinase (ALK) receptors ALK4, ALK5, and ALK7 that phosphorylate Smad2/Smad3 and 
thus activate downstream signalling pathways. In an attempt to find the mechanism of 
action behind the effect of SB on the cardiac reprogramming efficiency, Ifkovits el al. 
(2014) reported that specifically the inhibition of the TGF-β signalling component of 
the superfamily led to the increased reprogramming efficiency. A recent study by Zhao 
et al. (2015) confirmed these results, by achieving the highest yet reported cardiac 
reprogramming efficiency, 67%, by overexpressing HGMT cardiac TFs, miR-1 and miR-
133 combined with a small-molecule compound TGF-β inhibitor. It has previously been 
shown that direct reprogramming with GMT + miR-133 was mediated through 
suppression of TF gene Snail1, which is a downstream target of TGF-β (Muraoka et al. 
2014). It is therefore possible that the effect of TGF-β inhibition on direct cardiac 
reprogramming is mediated through downregulation of Snail1. Together these results 
suggest that inhibition of TGF-β signalling serves as a potential target for drug 
development in direct cardiac reprogramming. 
 
In addition to testing the effect of the small-molecule compounds in HNGMT-mediated 
cardiac reprogramming the effect of the compounds was also evaluated with HGMT-
transduced MEFs. There has been conflicting results regarding the effect of Nkx2.5 on 
the reprogramming efficiency as both an increase and decrease in the efficiency has 
been reported with the addition of Nkx2.5 (Ieda et al. 2010, Song et al. 2012, Addis et 
al. 2013). Here no difference in the reprogramming efficiency was found when 
comparing the two TF combinations (Ieda et al. 2010). Also, no difference in the effect 
of the small-molecule compounds was found between the two combinations.  
 
The small molecule screening platform was established succesfully. However, setting 
up a reprogramming thechnique is challenging and time-consuming and several 
questions were left unanswered and need to be confirmed in further studies. There 
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were also several limitations to the study that might affect the reliability of the results 
and need to be taken into account when interpreting the results. First of all, most of 
the data are preliminary results and more replicates are needed in order to confirm 
the current results. Also, great variability was seen in the results of the individual 
reprogramming experiments and more consistent results are needed before the 
platform can be used for actual screening.  
 
Further characterisation of the generated iCMs is necessary in order to validate the 
platform. Immunocytochemical staining for cTnT expression showed clearly organised 
sarcomeres in only a part of the iCMs while no sarcomere structure was observed in 
most of the generated iCMs. This indicates that most of the cells were immature and 
only partially reprogrammed. Also, only sporadic beating cells were observed. The 
generation of immature iCMs might become a problem in clinical applications, as they 
might trigger arrhythmias (Sadahiro et al. 2015). In order to further characterise the 
iCMs and assure complete direct reprogramming the gene expression pattern of the 
iCMs should be determined by RT-PCR, microarray or RNA sequencing. Further, action 
potential or calcium oscillations should be determined using a functional outcome 
measure. Also further optimisation of the reprogramming protocol is needed in order 
to achieve higher reprogramming efficiencies. 
 
Many questions and concerns remain regarding the potential of direct cardiac 
reprogramming as a future regenerative therapy for MI and HF. In order to achieve 
high enough reprogramming efficiencies for therapeutic application the underlying 
mechanism and barriers of direct reprogramming need to be determined. Determining 
the effect of small-molecule compounds on the reprogramming efficiency may help 
determine the relevant signalling pathways and targets for future drug development 
targeting direct cardiac reprogramming. Also, increased understanding of epigenetic 
regulation of cell fate and epigenetic barriers inhibiting cardiac reprogramming is 
needed in order to achieve the full potential of direct reprogramming.  
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7 CONCLUSIONS 
 
Direct cardiac reprogramming holds great potential as a regenerative therapy. As CFs 
play a major role in the pathogenesis of HF, direct reprogramming of fibroblasts to 
cardiomyocytes represents an attractive target for future HF therapies. Direct 
reprogramming has successfully been achieved both in vitro and in vivo. However, 
several issues, including low reprogramming efficiency, generation of immature 
cardiomyocytes and potential risk of genomic integration associated with the use of 
viral vectors, still remain to be resolved before the technique can be applied to clinical 
practice.  
 
The results of this M. Sc. thesis work demonstrate a method for in vitro small-molecule 
compound screening, which can be used to identify compounds that increase the 
efficiency of direct cardiac reprogramming or even replace cardiac TFs altogether. The 
results also verify previous publications that MEFs can be directly reprogrammed to 
iCMs by overexpression of both HGMT and HNGMT TF combinations. In accordance 
with recent research it was found that the reprogramming efficiency is significantly 
increased by treatment with the TGF-β inhibitor SB. None of the other tested small-
molecule compounds were found to have an effect on the reprogramming efficiency.  
 
As no statistical analysis was performed due to lack of replicates the results are, 
however, only directional and no real conclusions can be made based on these results. 
Further optimisation of the method and additional reprogramming experiments are 
needed in order to validate the established small-molecule compound screening 
platform. Nonetheless, these results set a foundation for finding small-molecules that 
in the future might be used to target direct cardiac reprogramming as a regenerative 
therapy for MI or HF. However, future research will show the true value of direct 
cardiac reprogramming in cardiac regeneration. 
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